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A B S T R A C T  
 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating and often 
life-long condition affecting over 20,000 New Zealanders. Symptoms include muscle and joint 
pain, severe fatigue, unrefreshing sleep, hypersensitivity to light and sound, and cognitive 
dysfunction. However, the condition lacks a reliable diagnostic biomarker, impairing patient 
diagnosis and treatment development.  Previous research has identified several key physiological 
areas of promise from which markers might come, including mitochondrial dysfunction, HPA-
axis impairment, immune alterations, increased oxidative stress and epigenome modifications.  
This project focuses on post-exertional malaise (PEM), a cardinal symptom of ME/CFS. Post-
exertional malaise is defined as an exacerbation of ME/CFS symptoms after physical, mental or 
emotional exertion. As PEM distinguishes ME/CFS from other fatigue-related conditions, it 
may aid in identifying the molecular basis of ME/CFS.  
To determine the molecular changes leading to this malaise, five ME/CFS-affected individuals 
and two healthy controls performed an exercise paradigm where they were made to cycle on an 
ergometer until their peak work rate was reached. 20 mL of blood was taken from each individual 
before performing the exercise, and after two exercise episodes that were 24 hours apart.  
Peripheral blood mononuclear cells (PBMCs) were purified from the blood by centrifuging on 
Ficol gradients. The mitochondrial function was determined on live cells using the Seahorse XF 
Cell Mito Stress Test Kit. The genomic DNA was extracted from the PBMCs and 8-hydroxy 2 
deoxyguanosine (a marker of oxidative stress) was determined using an 8-hydroxy 2 
deoxyguanosine ELISA Kit. Methylome changes were detected in the DNA by digestion of the 
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DNA and preparation of 40-220bp fragment libraries before performing Reduced 
Representation Bisulfite sequencing.  
A decrease in the mitochondrial function after the first exercise was observed in all ME/CFS 
individuals and one control. Contrary to existing literature, the ME/CFS group had, on average, 
a lower level of 8-hydroxy 2 deoxyguanosine compared to healthy controls.  
An average of 1.25% of DNA fragments were differentially methylated between the baseline 24-
hour and baseline and 48-hour samples. Results of a STRING protein network analysis on the 
differentially methylated fragments present in the promoter show interaction between 
upregulated mitochondrial, nervous system, immune function, and HPA-axis -associated genes. 
Additionally, hypermethylation and potentially decreased expression of POU3F4, a 
transcription factor with high expression levels in the basal ganglia (which regulates motor 
activity and motivation) provides evidence of how the PEM symptoms of increased fatigue and 
perceived exertion may arise. 
Whilst the molecular changes during PEM are varied and complex, these results contribute to 
the knowledge of the processes underlying the symptoms, and by proxy, the overall 




A C K N O W L E D G E M E N T S  
 
Firstly, I would like to thank my supervisor, Emeritus Professor Warren Tate. He has supported 
and championed me to an extent I did not anticipate from any supervisor. It has been an extreme 
privilege and pleasure to be under his mentorship for this year.  
Secondly, I would like to acknowledge the support of my co-supervisors, Associate Professors 
Aniruddha Chatterjee and Elizabeth Ledgerwood. Their expertise and advice have been so 
valuable.  
Furthermore, I want to thank Dr. Euan Rodger and Christina Edgar for all their assistance 
throughout the project.  
I also want to express my immense gratitude towards my flatmates Josiah, Thomas, Hannah, and 
Paida, for listening to me groan about the number of NanoDrops I needed to do and the 
frustration that is RStudio (even if you have no idea what that means!) 
My great thanks go out to my friends and family, who have supported me so greatly on my 
journey thus far. To my dad, especially, who has suffered from ME/CFS my entire life, and my 
mum who has supported him through it.  
Finally, I want to thank my fiancé Will. My dear, you have been so supportive of me throughout 
it all, even if it meant celebrating with me over my successes when your own experiments had 




Above all things, my praise goes to the LORD, who knows all things and is all things. He is my 
strength and my song, and the rock upon which I stand.    
v 
 
T A B L E  O F  CO N T E N T S  
 
 
ABSTRACT .................................................................................................................................................... I 
ACKNOWLEDGEMENTS ......................................................................................................................... III 
TABLE OF CONTENTS .............................................................................................................................. V 
LIST OF FIGURES ..................................................................................................................................... VII 
LIST OF TABLES ...................................................................................................................................... VIII 
LIST OF ABBREVIATIONS ....................................................................................................................... IX 
1. INTRODUCTION .............................................................................................................................. 1 
1.1. ME/CFS ...................................................................................................................................................................... 1 
1.1.1. Symptoms .................................................................................................................................................................. 2 
1.1.2. Diagnosis ................................................................................................................................................................... 2 
1.1.3. Treatment ................................................................................................................................................................. 4 
1.2. POST-EXERTIONAL MALAISE ............................................................................................................................... 6 
1.2.1. Post-Exertional Malaise and ME/CFS ................................................................................................................ 6 
1.2.2. Post-Exertional Malaise and Exercise Capacity .................................................................................................. 7 
1.2.3. Post Exertional Malaise and Cardiac Physiology ............................................................................................... 9 
1.3. THE MOLECULAR BASIS OF ME/CFS ................................................................................................................. 11 
1.3.1. ME/CFS and Mitochondrial Dysfunction ......................................................................................................... 11 
1.3.2. ME/CFS and the Cell Danger Response Hypothesis .......................................................................................... 13 
1.3.3. ME/CFS and Epigenetics ...................................................................................................................................... 14 
1.3.4. ME/CFS and Stress ............................................................................................................................................... 16 
1.4. THE POSSIBILITY OF ME/CFS SUBTYPES ............................................................................................................ 18 
1.5. CONCLUSION ...................................................................................................................................................... 20 
1.6. AIMS AND HYPOTHESES ...................................................................................................................................... 21 
1.6.1. Aims ........................................................................................................................................................................ 21 
1.6.2. Hypotheses ............................................................................................................................................................... 22 
2. METHODS ......................................................................................................................................... 23 
2.1. PARTICIPANT SELECTION .................................................................................................................................. 23 
2.2. PROCESSING OF BLOOD TO ISOLATE PBMCS .................................................................................................. 24 
2.3. MITOCHONDRIAL FUNCTION ANALYSIS .......................................................................................................... 26 
2.3.1. Day One .................................................................................................................................................................. 26 
2.3.2. Day Two .................................................................................................................................................................. 27 
2.4. EXTRACTION OF GDNA FROM PBMCS .......................................................................................................... 29 
2.5. OXIDATIVE STRESS ANALYSIS ............................................................................................................................ 30 
2.5.1. Day One .................................................................................................................................................................. 30 
2.5.2. Day Two .................................................................................................................................................................. 31 
2.5.3. Analysis ................................................................................................................................................................... 32 
2.6. DNA METHYLOME ANALYSIS ............................................................................................................................ 33 
2.6.1. Overview of RRBS Library Preparation Protocol .............................................................................................. 33 
vi 
 
2.6.2. MspI Digest ............................................................................................................................................................ 33 
2.6.3. DNA Purification of MspI Digest ....................................................................................................................... 34 
2.6.4. End Repair ............................................................................................................................................................. 35 
2.6.5. DNA Purification of End Repair ....................................................................................................................... 35 
2.6.6. 3’ End Adenylation ............................................................................................................................................... 36 
2.6.7. Adaptor Ligation ................................................................................................................................................... 36 
2.6.8. DNA Purification of Adaptor-Ligated DNA .................................................................................................... 38 
2.6.9. Bisulphite Conversion ............................................................................................................................................ 38 
2.6.10. Semi-Quantitative PCR .................................................................................................................................. 40 
2.6.11. Large-Scale PCR ............................................................................................................................................... 43 
2.6.12. AMPure Bead Purification Library Quantification .................................................................................. 44 
2.6.13. Bioanalyzer High Sensitivity DNA Assay ..................................................................................................... 45 
2.6.14. Data Analysis ................................................................................................................................................... 46 
3. RESULTS ........................................................................................................................................... 49 
3.1. MITOCHONDRIAL FUNCTION ANALYSIS .......................................................................................................... 49 
3.2. OXIDATIVE STRESS ANALYSIS ............................................................................................................................ 54 
3.3. DNA METHYLOME ANALYSIS .......................................................................................................................... 60 
3.3.1. RRBS Library Preparation .................................................................................................................................. 62 
3.3.2. Data Analysis ......................................................................................................................................................... 67 
3.3.3. Whole Genome Changes ....................................................................................................................................... 68 
3.3.4. Promoter-Located Changes ................................................................................................................................... 70 
4. DISCUSSION ..................................................................................................................................... 76 
4.1. SUMMARY ............................................................................................................................................................ 76 
4.2. MITOCHONDRIAL FUNCTION ........................................................................................................................... 76 
4.3. OXIDATIVE STRESS ............................................................................................................................................. 78 
4.4. DNA METHYLOME ............................................................................................................................................ 79 
4.4.1. Context .................................................................................................................................................................... 79 
4.4.2. Overall changes ...................................................................................................................................................... 80 
4.4.3. Metabolic Alterations............................................................................................................................................ 80 
4.4.4. Immune System Alterations ................................................................................................................................. 81 
4.4.5. Nervous System Alterations .................................................................................................................................. 81 
4.5. LIMITATIONS & FUTURE DIRECTIONS ............................................................................................................. 83 
4.6. CONCLUSIONS ..................................................................................................................................................... 84 




L I S T  O F  F I G U R E S  
 
FIG 1.1: Graphical depiction of metabolic impairments predicted to cause ME/CFS and 
PEM symptoms. ................................................................................................................................. 10 
FIG 1.2: Duration of PEM in Two Study Cohorts. ..................................................................... 10 
Fig 1.3: Summary Diagram of Current Literature’s Understanding of ME/CFS. ............... 20 
FIG 2.1: Depiction of Peripheral Blood Mononuclear Cell (PBMC) extraction. .................. 25 
FIG 2.2: Overview of RRBS Library Preparation Protocol ....................................................... 33 
FIG 3.1: Seahorse XF Cell Mito Stress Test Profiles. .................................................................. 50 
FIG 3.2: Differences in Mitochondrial Function Markers in ME/CFS Individuals vs 
Controls. ............................................................................................................................................. 52 
FIG 3.3: Differences in The Levels of ATP Production Per Individual, Over Time. ............ 53 
FIG 3.4: Comparison of Guanosine and 8-OHdG Structures. .................................................. 56 
FIG 3.5: Standard Curve of 8-OHdG for oxidative stress assay. .............................................. 57 
FIG 3.6: Concentration of 8-OHdG in ME/CFS Individuals vs Controls, over time. ......... 57 
FIG 3.7: 8-OHdG Concentration in Fresh vs Frozen samples ................................................... 58 
FIG 3.8: Individual Differences in The Concentration Of 8-OHdG in ME/CFS Individuals 
vs Controls, Over Time. ................................................................................................................... 59 
FIG 3.9: Example of Un-degraded gDNA. .................................................................................... 62 
FIG 3.10: Depiction of RRBS library preparation. ..................................................................... 63 
FIG 3.11: Successful Amplification of Digested DNA. .............................................................. 64 
FIG 3.12: Unsuccessful Amplification of Digested DNA. ......................................................... 65 
FIG 3.13: Bioanalyzer plots of RRBS libraries sent for Sequencing. ....................................... 66 
FIG 3.14: Volcano Plots Displaying Differential Methylation Between Baseline and 24 h 
Samples, and Baseline and 48 h Samples, Across Entire Genome. ........................................... 68 
FIG 3.15: Genomic Location of the CpGs in Significantly Differentially Methylated 
Fragments in ME016 Baseline vs 24 h And Baseline vs 48 h Comparisons. ........................... 71 
FIG 3.16: STRING Pathway of Significantly Differentially Methylated Promoter-Located 





L I S T  O F  T A B L E S  
 
TABLE 2.1 Volume of Seahorse XF base medium to add to the Seahorse XF Cell Mito Stress 
Test Kit Reagents. ............................................................................................................................ 27 
TABLE 2.2: Volume of Seahorse XF Base Medium and Prepared Stocks To Add For Seahorse 
Experiment. ........................................................................................................................................ 28 
TABLE 2.3: Volume of Reagents to Add to single-strand DNA. ............................................... 31 
TABLE 2.4: Reaction mixture for MspI digest ............................................................................. 34 
TABLE 2.5: Adaptors Used in RRBS Library Preparation. ....................................................... 37 
TABLE 2.6: Assembly Details for Semi-Quantitative PCR........................................................ 40 
TABLE 2.7: Semi-Quantitative PCR Protocol. .............................................................................. 41 
TABLE 2.8: Assembly Details for Large-Scale PCR..................................................................... 43 
TABLE 2.9: Large-Scale PCR Protocol. .......................................................................................... 43 
TABLE 2.10: Assignment Conditions for Genomic Location of Fragment............................. 47 
TABLE 3.1: Quality and quantity of gDNA used in oxidative stress experiments. ............... 55 
TABLE 3.2: Quality and quantity of gDNA used in DNA methylome experiments. ............ 61 
TABLE 3.3: Features of Samples After Sequencing. .................................................................... 67 
TABLE 3.4: Top Five Significantly Differentially Methylated Genes Between Baseline and 
24-Hour Samples Across Entire Genome. .................................................................................... 69 
TABLE 3.5: Top Five Significantly Differentially Methylated Genes Between Baseline and 
48-Hour Samples Across Entire Genome. .................................................................................... 69 
TABLE 3.6: All Promoter-Located Genes That Were Significantly Differentially Methylated 
in Either B v 24 or B v 48 h. ............................................................................................................ 72 
TABLE 3.7: Promoter-Located Genes Significantly Differentially Methylated Across Entire 




L I S T  O F  A B B R E V I A T I O N S  
 
Abbreviation Definition 
8-OHdG 8-hydroxy-2' -deoxyguanosine 
CpG A cytosine-guanine dinucleotide 
DMAP Differential Methylation Analysis Program 
FDR False-Discovery Rate 
HPA-axis Hypothalamic-Pituitary-Adrenal (HPA)-axis 
ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 
Msp1 A restriction enzyme commonly used to prepare DNA methylome 
libraries as it cleaves at C|CGG sites 
PBMCs Peripheral Blood Mononuclear Cells 
PCR Polymerase Chain Reaction 
PEM Post-Exertional Malaise 





















1 .  I N T R O D U C T I O N  
 
1.1. ME/CFS 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating condition 
that affects an estimated 20,000 New Zealanders1, yet no diagnostic marker currently exists, 
making diagnosis extremely difficult2.  
Though it was first recorded internationally in 1934, one of the first clusters of the disease 
occurred twenty-one years later at the Royal Free Hospital, London (United Kingdom)3, 4. It was 
classified as an epidemic of unknown aetiology and coined ‘Benign Myalgic Encephalomyelitis’, 
with patients experiencing sore muscles and inflammation of the brain3.  
Following this, a 1984 infection in Incline Village, Nevada, led to “Chronic Fatigue” in ninety 
residents5. The inclusion of the common symptom “fatigue” in the name and the absence of a 
diagnostic test caused many US practitioners to underestimate the severity and legitimacy of 
ME/CFS. Unfortunately, many patients experienced medical gaslighting6. In the UK, ME/CFS 
was considered a perception disorder or a “figment of the patient’s imagination”.  
Despite significant biochemical and physiological evidence of the disease, a similar view exists 
today, where a March 2021 Wall Street Journal opinion article presented long-COVID-19, which 
overlaps with many ME/CFS symptoms, as a mental illness rather than a biologically based 
disease7.  
As ME/CFS is primarily a post-viral disease, its incidence is said to soar given the current COVID-
19 pandemic8, displaying the same trend in the 2003 SARS outbreak9. Less than two years since 
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the first case of COVID-19, over two hundred New Zealanders suffer from long-COVD-1910. 
Although this drastic number is deeply saddening, the increased time and resources allocated to 
researching long-COVID may have a trickledown effect for ME/CFS research, allowing us to 
develop effective treatments, understand disease pathogenesis, minimise the global economic 
load, and decrease patient suffering.  
1.1.1. Symptoms 
Key characteristic symptoms of ME/CFS include severe fatigue, unrefreshing sleep, 
hypersensitivity to light and sound, cognitive dysfunction, and post-exertional malaise 
(PEM), where ME/CFS symptoms worsen after exposure to a form of exertion6. Other 
debilitating symptoms include muscle/joint pain, headaches, and neuroendocrine, immune, 
and autonomic dysfunctions like orthostatic intolerance (commonly perceived as dizziness)6.  
Additionally, ME/CFS has a characteristic long-term nature, and most affected individuals 
suffering life-long—only 5% of individuals recover 11, 12. Disease progression is typified by 
periods of relapse and remission8, with one-third of patients deteriorating to house/bed-
bound4.   
1.1.2. Diagnosis 
Nonetheless, as diagnosis of ME/CFS is imprecise by nature, defining what “recovery” is a 
challenge in and of itself. Diagnosis is currently based on physical examination, case history, 
and exclusion of other fatigue-related conditions and must persist for ≥ six months before 
diagnosis6, 13, 14.  
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 At least twenty different clinical diagnostic criteria for ME/CFS have been reported, though 
the most commonly used are the Fukuda definition (1994)15, Canadian Consensus Criteria 
(2003)16, the International Consensus Criteria (2011)17, and the National Academy (Institute) 
of Medicine definition (2015)6. This complex diagnosis system is problematic, leading to an 
inability to compare study cohorts using different diagnostic criteria. Fukuda definition, for 
example, does not require the presence of PEM, despite PEM being the critical symptom that 
separates ME/CFS from other fatigue-related conditions6, 18, 19. Additionally, many of the 
minor symptoms included in these criteria are also present in those with clinical depression, 
which leads to misdiagnosing people with clinical depression with ME/CFS. The Canadian 
Consensus Criteria16, which requires the presence of PEM, is likely the most widely accepted 
and is appropriate for both clinical and research use. Despite this, most studies published use 
the Fukuda criteria for the diagnosis of ME/CFS.  
Because the diagnosis process of ME/CFS is currently so complex, an effective biomarker is 
desperately needed, as this would simplify the diagnosis process, standardise study cohorts, 
and decrease the time between symptom onset and clinical diagnosis. Several groups have 
made headway in developing an effective biomarker. For example, a recent study by 
Sweetman et al. (2019) showed that phosphorylated Protein Kinase R (involved in the 
innate antiviral immune response) in Peripheral Blood Mononuclear Cells (PBMCs) was 
significantly higher in ME/CFS individuals compared to healthy controls20. Another study 
from Dr Ron Davis’ group at Stanford University showed that when subjected to 
hyperosmotic stress by NaCl, ME/CFS individuals exhibited an pattern distinct from 
controls21. However, the specificity of these biomarkers to ME/CFS and not other diseases 
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and whether they are also present in the early stage of disease progression is yet to be 
determined. Therefore, these experiments should be replicated in recently diagnosed 
individuals and those with similar conditions (such as Multiple Sclerosis and clinical 
depression).  
1.1.3. Treatment 
The lack of understanding of the disease, and in part, the delay in public acceptance, limited 
the development of effective treatments for ME/CFS8. Various non-pharmacological 
therapies for ME/CFS have been developed, including Graded Exercise Therapy (GET) and 
Cognitive Behavioural Therapy (CBT), though the effectiveness of these approaches is hotly 
debated2, 22, 23, with some individuals experiencing a relapse of illness rather than recovery22. 
A 2020 release by the National Institute of Health and Care Excellence advised practitioners 
against recommending “any therapy based on physical activity or exercise as a treatment or 
cure for ME/CFS” (such as GET or APT) and cautioned against using CBT as a treatment 
or cure. However, it may be suitable for psychological support24.  
Many patients instead rely on palliative measures such as analgesics, nutritional supplements 
like Vitamin B12, or low dose naltrexone (proposed to have anti-inflammatory effects and 
increase endorphin production). Though these treatments can be successful25, many have no 
effect, and some even harm patients, causing symptom flare-ups 8. Unfortunately, this 
inconsistency in results is all too common, with many ME/CFS individuals experiencing 
hypersensitivity to the medicines that would help manage their disease. This paradox means 
that careful testing of treatments is required to identify those that may trigger a reaction8.   
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Currently, ME/CFS treatments are “best-estimates” of what will alleviate symptoms, as little 
is known about the aetiology of the disease. Some patients trial treatments based on their 
success in others rather than because they compensate for their dysfunctional pathway (as in 
diabetes mellitus and insulin, for example). Finding the cause of ME/CFS is further 
complicated by its genetic nature. ME/CFS is likely a disease of multiple weak but 
confounding effects, where individual variants do not contribute greatly to overall disease 
pathogenesis. Employing an -omics approach, which looks at the global changes of an 
individual rather than particular aspects of their biochemistry, may be more appropriate. 
However, an -omics approach often involves hundreds of participants—a difficult feat for 
those with chronic illness, where minor doctor appointments can trigger a PEM flare-up. 
Therefore, a “precision medicine” approach should be taken, focussing on the molecular 
changes within a ME/CFS individual over time, studying the differences of a small number 
of patients in great detail. Whilst this can decrease the probability of finding rare variants, 
recruiting the required number of participants is more achievable than a Genome-Wide 
Association Study (GWAS), which requires hundreds of patients. If ME/CFS research 
becomes increasingly standardised, other precision medicine studies may share data, 
simulating a “GWAS”-type investigation. Measuring changes within one ME/CFS 
individual over time, such as during PEM, may be extremely valuable, as it may tell us which 
processes are involved in ME/CFS symptom presentation. PEM is an especially suitable 
candidate, as many biological changes occur physiologically and at the biochemical and 
molecular levels.  
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This thesis focuses on the molecular changes that occur during PEM, and in more detail, how 
mitochondrial function, epigenetics, and oxidative stress levels change throughout the 
malaise. Throughout this, it attempts to isolate which specific processes are involved in PEM 
presentation. Because PEM is a distinguishing factor of ME/CFS individuals and healthy 
controls, these differences may provide insight into ME/CFS etiopathology, uncovering new 
targets for diagnostic biomarkers and potential treatments.  
1.2. Post-Exertional Malaise  
1.2.1. Post-Exertional Malaise and ME/CFS 
Post-exertional malaise (PEM) can be defined as “a worsening of a patient’s symptoms and 
function after exposure to physical, [emotional] or cognitive stressors that were normally 
tolerated before disease onset” 6. This “symptom-relapse” may also be delayed relative to the 
triggering event26. The Institute of Medicine of the National Academies regards this as the 
second most essential symptom of ME/CFS, exceeded only by fatigue6. 
PEM is most prevalent in ME/CFS individuals (79-100%18, 19, 27) compared to healthy 
controls (4-6%18, 19), though it can occur in other similar diseases, such as clinical depression 
(19 to 20%19) and multiple sclerosis (52%18). In this context, identifying what causes PEM 
would uncover novel therapeutic targets and increase our understanding of how and why 
these diseases occur.  
Many ME/CFS researchers have previously attempted to identify the cause of ME/CFS by 
using a traditional biochemistry approach, comparing how small components of ME/CFS 
cells differ from healthy ones. However, to uncover 1) why the body rarely recovers from this 
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state and 2) the “root cause” of the disease, a big picture approach may be more appropriate. 
Therefore, in-depth “-omics” approaches should be used. 
Existing studies incorporating this approach show promising findings. First, in a 
metabolomic analysis, Naviaux and colleagues (2016) found that ME/CFS individuals had a 
hypometabolic state similar to hibernation28. Another study on the transcriptome of 
ME/CFS individuals found several elevated transcripts associated with the circadian rhythm, 
which, if disrupted, shows ME/CFS-like symptoms. Finally, a recent proteome study by 
Germain et al. (2021) identified the novel involvement of ephrins (the largest known 
subfamily of receptor tyrosine kinases), which are active in many tissues supporting the 
finding that ME/CFS is multisystemic29.  
As displayed above, -omics studies provide an unbiased insight into disease aetiology, looking 
at the whole individual rather than just an aspect. As ME/CFS has already shown itself to be 
unlike other diseases, this is likely the best way of unveiling the true cause of ME/CFS. As 
stated earlier, the PEM response is a prime candidate for isolating which pathways are 
involved in ME/CFS symptom presentation, and so shifting -omics research towards the 
changes in PEM should be a keen focus of ME/CFS research in future. 
1.2.2. Post-Exertional Malaise and Exercise Capacity 
One of the current hypotheses regarding the cause of PEM is exercise phobia. ME/CFS 
individuals understandably avoid symptom relapse, including PEM triggers, such as exercise. 
This aversion leads many researchers to believe that “kinesiophobia”—the excessive, 
irrational, and debilitating avoidance of movement or activity in anticipation of painful 
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injury or reinjury, is a prominent cause of PEM30. This exercise aversion is ultimately 
explained by a reduced level of exercise due to fatigue, leading to muscle degeneration 
(deconditioning) and thus an increase in exercise difficulty. As a result, the level of tolerable 
exercise is lower than before disease onset. This “increased vulnerability” to the stressor 
(exercise) parallels the definition of the PEM state: “a worsening of a patient’s symptoms and 
function after exposure to physical . . . stressors that were normally tolerated before disease 
onset”.  
Despite this convincing theory, many investigations have largely disproven this. One study 
using the Tampa Scale of Kinesiophobia, a reliable measure of exercise phobia, showed that 
whilst ME/CFS-affected individuals had a higher level of baseline anxiety than sedentary 
controls, this did not increase with exercise as it would with an irrational/excessive fear31. If 
the theory that kinesiophobia causes PEM is true, ME/CFS individuals should have had a 
higher level of anxiety during exercise than sedentary controls. This evidence dismisses 
kinesiophobia as a cause of PEM. The paper’s authors reason that this kinesiophobia 
theory32, 33 may be due to studies including ME/CFS individuals with comorbid psychiatric 
disorders, which do have a proven kinesiophobia which would confound the results.  
Nonetheless, a modified perception of exercise may still influence PEM manifestation. Some 
argue that PEM is caused by increased perceived exertion, where those with ME/CFS sense 
that a physical activity is more laborious and strenuous compared to what is perceived by 
healthy controls34. An early paper on the topic35 and a recent meta-analysis34 found that 
ME/CFS individuals perceive a higher exertion level than healthy controls following the 
same amount of exercise. ME/CFS individuals also have a decreased pain threshold36, 37, 
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indicating that a disruption in brain signalling controlling exertion- and pain perception is 
somewhat responsible for PEM.   
1.2.3. Post Exertional Malaise and Cardiac Physiology 
Other probable contributors of PEM are cardiovascular and metabolic dysfunctions. There 
are numerous reports of lowered ATP synthesis following exercise38, 39, increased lactate 
levels38, 40, 41, and decreased maximal oxygen uptake (VO2 max)40, 42 in ME/CFS individuals. 
However, whether VO2 max levels are affected is contended, with a paper by Sargent et al. 
(2002) showing no difference between ME/CFS individuals and healthy controls43. The 
authors credit the observed but “untrue” differences in VO2 max to gender pooling. Females 
biologically have a lower VO2 max44 and in some studies38, 39, the ME/CFS group have higher 
numbers of females than controls. When authors pool both male and female results to 
represent ME/CFS individuals’ vs controls’ VO2 max levels, the results can skew, displaying 
a false trend.  
Although Sargent et al. 43 raise a valid point, it is probable that those with ME/CFS still have 
a lower VO2 max than controls, as this association is still found in a study with females only45. 
Interestingly, this decreased VO2 max reduces the amount of oxygen and thus ATP in the 
body, triggering upregulation of glycolysis. This switch in metabolism increases pyruvate 
and lactate levels in the body. When lactate builds up, and ATP levels are insufficient, fatigue, 
pain, cognitive impairment, and other symptoms similar to ME/CFS are present46 (see FIG 
1.1 ). These results strongly suggest that cardiovascular and metabolic impairments are 
heavily implicated in PEM symptom presentation.  
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As with much of ME/CFS research, there are many discrepancies between papers 
investigating PEM. These are likely due to differences in cohort compositions (% female, % 
patients bed-ridden), criteria used for diagnosis, the level of patient exertion (maximal or sub-
maximal exercise), test design (single or multiple exercise tests), and difference in time 
between when pre-and post-exercise samples were taken. 
Repetition of exercise tests is hugely important, as this allows the measurement of the PEM 
state. For example, VanNess et al. (2007)  found no significant differences in VO2 max or 
anaerobic threshold between ME/CFS cases and healthy controls after a single exercise (i.e. 
not during PEM)42. However, upon repeating this test, these values were significantly lower 
in ME/CFS individuals than controls because of the effects of PEM. These results indicate 






FIG 1.2: Duration of PEM in Two Study Cohorts.  
Graph based on data from VanNess et al. (2010) (dotted)47 and Davenport et al. (2011) (solid)48. Recovery Rate of ME/CFS-affected 
individuals versus sedentary controls. Data points plotted are those stated in respective papers, assuming that no individuals had 
recovered at the time of exercise. Trend lines were not extrapolated. * = 60% of VanNess cases took ≥ five days to recover from the 
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These facts display an acute problem in the field: the disparity between the measurement 
time for peak PEM and when PEM actually peaks. Many study designs use 24 hours post-
exercise as a measure of PEM state 36, 42, 45, 49, 50, potentially explaining the lack of difference 
found between cases and controls 45. However, VanNess and colleagues (2010) showed that 
60% of ME/CFS patients took ≥ five days to recover from exercising until voluntary 
exhaustion47. In contrast, all control individuals had recovered by day two. Davenport et al. 
(2011) found similar results, where 45% of ME/CFS-affected individuals were incompletely 
recovered after one week, yet 93% of controls considered themselves recovered after 24 
hours48.  
Therefore, when the PEM state peaks must be determined, which should be used as the 
standard time for “PEM state” sample collection.  Performance of multiple subsequent 
exercise tests must also be ensured. This consistency will increase the capacity to compare 
PEM studies, which is crucial for ME/CFS studies where only small cohorts can often be 
used.  
1.3. The Molecular Basis of ME/CFS 
1.3.1. ME/CFS and Mitochondrial Dysfunction 
The cardinal symptom of ME/CFS is fatigue, indicating that energy and thus metabolism is 
a significant aspect of disease pathogenesis. This association spurred many researchers to 
investigate mitochondrial function, showing that mitochondrial dysfunction correlates with 
PEM severity, likely due to an impaired ability to produce energy and lactate build-up, as 
previously discussed. Thus, researchers historically posited mitochondria as the “central 
cause” of ME/CFS51. Those with other mitochondrial dysfunction diseases portray similar 
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symptoms (fatigue, weakness, and exercise intolerance)52, and further evidence showed 
mitochondrial aberrations in ME/CFS affected individuals.  
Many studies report decreased ATP production in ME/CFS 38, 51, 53-56. These findings suggest 
that defects in ATP production may lead to the symptoms of fatigue experienced by those 
affected. Other studies show little/no difference in the steady-state ATP levels between 
patients and controls56, 57, with one even reporting an increase in ME/CFS ATP levels 
compared to healthy controls58. However, as Missailidis and colleagues (2019) raise, this 
similarity in ATP levels does not necessarily equate to a lack of ATP synthesis defects59. 
Instead, this may be the body compensating for impairments in oxidative phosphorylation 
by upregulating other ATP-producing pathways such as glycolysis, resulting in a perceived 
increase in ATP levels59. One paper did indicate that glycolysis did not vary dramatically from 
controls, though the authors admit that this may be due to the small sample size54. 
Other studies in ME/CFS individuals have reported disrupted proton gradients54-56, 
decreased membrane potentials55, 56, as well as lower levels of electron transport chain 
components such as Coenzyme Q1053, 60, and reduced efficiency of Complex V56, 61. 
Together, these results indicate that mitochondrial dysfunction is present in ME/CFS, 
though whether this is a cause or consequence of the disease is yet to be determined.  
One intriguing hypothesis is that mitochondrial defects are not the root cause of the fatigue 
experienced in ME/CFS but instead result from disruptions in “upstream” pathways. Strong 
evidence for this is the marked increase in lipid peroxidation of mitochondrial membranes in 
ME/CFS affected individuals compared to controls. When lipids are oxidised, they form 
“neoepitopes”—new antigens recognised as foreign by the immune system. These 
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neoepitopes elicit an immune response, destroying mitochondrial membranes and 
generating more reactive oxygen species, perpetuating this cycle.  However, this is very early 
research, and no evidence of autoantibodies against mitochondrial membrane lipids have 
been found to date 62.  
1.3.2. ME/CFS and the Cell Danger Response Hypothesis 
Another hypothesis stems from Schreiner and colleagues’ (2020) recent work on Human 
Herpesvirus-6 (HHV-6), mitochondrial fragmentation and ME/CFS63. Here, reactivation 
of HHV-6 (known to trigger ME/CFS) altered mitochondrial proteins involved in 
β-oxidation and amino acid metabolism and downregulated the expression of antioxidants 
such as manganese-dependent superoxide dismutase 2 (SOD2), and also decreased 
cytoplasmic and mitochondrial ATP. Interestingly, serum from ME/CFS affected 
individuals induced a similar effect. Lower cellular energy levels cause mitochondrial 
fragmentation, which reduces the cell’s ability to mount an innate immune response. In viral 
infections, this is advantageous, as it allows persistent infection. However, the authors 
questioned whether this mitochondrial fragmentation in ME/CFS affected individuals 
triggers the pro-inflammatory cell danger response in compensation. The cell danger 
response, similar to dauer, is caused by exposure to a stress event, often a viral infection, in 
which the cell alters its metabolism and cell structure to prevent viral replication or 
physical/chemical damage64. Virus-induced disruption of mitochondria and oxidative stress 
levels further supports the hypothesis that mitochondrial dysfunction is due to alterations in 
upstream pathways.  
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1.3.3. ME/CFS and Epigenetics 
Other angles of research include the genetic basis of ME/CFS. ME/CFS is an acquired 
disease. One may be predisposed to acquired conditions, but disease development is 
dependent on exposure to external stimuli (in this case, viruses, bacteria, severe abuse, and 
other stressors). These then induce a change, which often affects the epigenetics of an 
individual. Studying the epigenetics of those with ME/CFS may identify which genes and 
pathways are involved in the disease and how they contribute to the pathological state. 
Methylation occurs via the addition of a methyl group to a cytosine base present in the DNA. 
However, this can only occur when the cytosine (C) is located next to a guanine (G). 
Therefore, sites that can be methylated in the genome are called “CpG” sites, indicating a 
cytosine linked to a guanine via a phosphate bond. High amounts of methylation 
(hypermethylation) in genes prevent the transcription machinery from accessing the gene and 
producing a gene product. Low amounts of methylation (hypomethylation), however, allow 
the transcription machinery to access the gene, producing the gene product it encodes.  
Only six papers on this topic exist at the time of writing, but all six have shown clear evidence 
that the epigenetics of ME/CFS-affected individuals differs from that of controls65-70. 
Differentially methylated pathways include metabolism65-70, the immune system65-70, 
apoptosis 65, 68, 69 and kinase activity 65, 66, 69, further confirming the involvement of 
metabolism and the immune system in ME/CFS. Additionally, Helliwell et al. (2020) 
noticed a significant trend. Between three of the studies on PBMCs67, 69, 70, a total of 122 genes 
were differentially methylated. Interestingly, all three studies showed differential 
methylation of the same 42 genes, implicated in calcium signalling, glucagon signalling, 
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apoptosis, and nitric oxide production through the NFκB pathway (see Helliwell et al., 2020, 
Additional file 1: Excel file “Gene_Overlaps”). These papers also show hypomethylation of 
genes in neurotransmitter pathways, with Helliwell et al. (2020) suggesting that this elicits a 
stress response via cortisol, triggering ME/CFS symptom presentation.   
Further studies should investigate whether demethylation of these genes leads to similar 
symptoms (such as fatigue and exercise intolerance) and the cellular abnormalities 
characteristic of ME/CFS (energetic defects and oxidative stress) and whether epigenetic 
changes also occur during the PEM response. Results from this may indicate which genes are 
involved in the PEM process, why it presents, and whether they can be targeted 
therapeutically. 
Despite evidence of differential methylation, the direction in which this occurs is still 
debated. Three papers show increased methylation 66-68; two show decreased 65, 69, and the 
most recent paper on the topic reports no difference in methylation level between ME/CFS 
cases and controls70. Determining this is important, as it may allow us to use drugs such as 
azacytidine (used to treat forms of cancer) to decrease global methylation in ME/CFS 
patients and thus allow increased expression of the knocked-down pathways. Much of the 
discrepancies in results could be explained by differences in tissue type, statistical analyses, 
and differential methylation cut-off values. Also evident throughout ME/CFS research is 
cohort composition, varying in the female: male ratio, number of cases and controls, and the 
inclusion of house/bed-bound patients. Because these variations greatly influence results, 
research should shift to standardise the protocols used to study this.  
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Despite the strong evidence of differential methylation between ME/CFS individuals and 
healthy controls, it remains unknown whether methylation is a cause or consequence of the 
condition. Therefore, more longitudinal studies on the epigenetics of ME/CFS affected 
individuals, or even those suspected to develop the disease would be of great value, indicating 
how gene expression changes throughout the disease development and whether these 
epigenetic changes are pre-existing or a product of the disease. 
1.3.4. ME/CFS and Stress 
1.3.4.1. HPA-AXIS IMPAIRMENT IN ME/CFS 
Much of ME/CFS research has focused on stress, and more widely, the hypothalamic-
pituitary-adrenal (HPA)-axis, said to be the stress regulator of the body. A circulating 
hypothesis is that the HPA-axis is impaired in ME/CFS, though whether it has an 
increased or decreased sensitivity to its ligands is debated71-74.  
A review by Tomas et al. (2013) posits that NR3C1, encoding the glucocorticoid receptor 
(where cortisol and other glucocorticoids bind), is hyper-methylated, thus reducing its 
expression75. Other studies, however, found hypo-methylation of NR3C1 in ME/CFS 
individuals, suggesting that they have an increased sensitivity to glucocorticoids 65, 76. 
These results support data from de Vega et al. (2017), which showed that ME/CFS 
individuals stratified into two subtypes—glucocorticoid hypersensitive and those with 
normal sensitivity67.  
Further complicating these findings is that low cortisol levels cause many of the effects 
observed in ME/CFS, such as orthostatic hypotension and reduced cerebral perfusion, 
which leads to dizziness, fatigue, exercise intolerance75, 77. However, hypomethylation of 
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NR3C1 may instead compensate for the lower baseline cortisol levels found in some 
studies78, 79. Despite this, many of these papers have low statistical power76 or loci of 
weak effect67, so confirmation of these findings is necessary. 
The ambiguity of the results limits our ability to conclude whether Glucocorticoid 
Receptor hyper or hypofunction is linked to ME/CFS, though it is likely impaired. The 
existence of ME/CFS subtypes, however, may explain this contradiction.  
1.3.4.2. ME/CFS AND OXIDATIVE STRESS 
As ME/CFS is an inflammatory condition, there has been much research on whether 
ME/CFS individuals experience increased levels of oxidative stress 80, 81. Oxidative stress 
occurs when the number of reactive oxygen species (ROS) outweighs the number of 
reducing molecules (aka antioxidants) such as Glutathione, Zinc, and Coenzyme Q1080. 
ROS can be formed due to decreased antioxidants, infection, or dysfunctional oxidative 
phosphorylation80, 82.  
As discussed previously in section 1.3.1, oxidative stress is extremely damaging. Outside 
of mitochondria, oxidative stress has many other implications with ME/CFS. 
Researchers have attempted to determine a difference in oxidative stress levels between 
ME/CFS individuals and healthy controls and whether this contributes to the pathology 
of the condition 53, 60, 82-85. However, evidence of this is uncertain. In a study by 
Richards et al. (2000), four oxidative stress markers (oxidised haemoglobin, MDA, MCV 
and 2,3-DPG) were increased up to 2.34-fold in ME/CFS patient blood compare to that 
of healthy controls82.  
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Another study, focussing on DNA damage through the oxidative stress marker 8-
hydroxy-deoxyguanosine, showed a significant increase in ME/CFS individuals 
compared to controls60. Several studies have reported elevated lactate levels, which 
promotes oxidative stress38, 40, 41, 57. Two studies show a marked increase in lipid 
peroxidation53, 84. (82) also attempted to identify how this correlated with post-exertional 
malaise severity. However, confidence intervals for this paper overlapped considerably, 
invalidating their results84. Ghali et al. (2019) did, however, show that lactate levels 
increase with PEM symptom severity41. Furthermore, Jammes et al. (2000) showed that 
ME/CFS affected individuals had a slightly elevated baseline level of three antioxidants 
(including glutathione and ascorbic acid), but these results were not statistically 
significant83.  
Nonetheless, no studies have disproven the difference in oxidative stress levels between 
ME/CFS individuals and healthy controls. Several papers have also shown that this 
oxidative stress increases proportionally to ME/CFS symptom severity57, 82, 86, indicating 
a vital role in ME/CFS symptom presentation. However, as with other areas of promise, 
the root cause of this oxidative stress and whether it is a cause or consequence of ME/CFS 
is yet to be determined.  
1.4. The Possibility of ME/CFS Subtypes 
Several papers have shown evidence of ME/CFS subtypes. Research from Lane et al. (1998) 
showed ME/CFS individuals stratified into two groups: those with abnormal lactate responses 
to exercise testing, exhibiting intracellular acidosis and severe metabolic disturbances, and 
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ME/CFS individuals with normal metabolism and lactate responses38. Interestingly, those with 
abnormal responses to exercise had a significantly lower level of type I muscle fibres, which have 
the largest capacity to generate ATP, indicating that they physiologically had a reduced capacity 
to produce ATP, thus needed to compensate by increasing lactate production. However, it is 
essential to note that this exercise was neither a maximal exercise test nor did it involve repeated 
exercise to capture the effect of PEM. Additionally, the diagnosis criteria used (The Oxford 
Criteria) does not require PEM for diagnosis, creating a heterogeneous patient cohort. Therefore, 
it is difficult to conclude whether these results are accurate or due to these inconsistencies.  
Nonetheless, genetic/epigenetic research edifies the existence of ME/CFS subtypes. Early studies 
in the genome of ME/CFS individuals identified seven subtypes, differentiated by expression 
values for 88 genes correlated with symptom severity and clinical phenotype87, 88. More recently, 
de Vega et al. (2017) identified four ME/CFS subtypes based on methylome alone, differentiated 
by the methylation patterns of immune response genes, differences in physical functioning, and 
severity of PEM89. The group also identified subgroups with distinct glucocorticoid sensitivity67.  
This finding explains why treatments work well for some ME/CFS individuals, whilst others 
experience no difference or harm. By establishing which ME/CFS subtypes exist, the patient’s 
subtype can be determined, thus allowing the development of personalised treatment and 










To conclude, whilst ME/CFS research shows much promise (especially in the areas of 
mitochondrial function, epigenetics, oxidative stress, and subtyping), understanding the exact 
path of disease progression remains out of grasp. Several scholars suggest conducting genome-
wide association studies with large cohorts, as this will unveil the rare variants culminating in 
causing disease14. However, this may be unachievable, as study participation triggers PEM, the 
participation rate may be low and skewed to including patients with less severe ME/CFS. 
However, by standardising study design, using consistent diagnosis criteria, PEM “peak” sample 
collection time, and statistical thresholds (especially in epigenetics), comparison between papers 
is more achievable, in part overcoming this limitation.   
A 
B 
Fig 1.3: Summary Diagram of Current Literature’s 
Understanding of ME/CFS.  
Left shows summary diagram. Right shows examples of different 




Future research should focus on a “personalised medicine approach”: defining ME/CFS 
subtypes and the epigenetics of ME/CFS, especially how this varies during PEM. It should also 
investigate mitochondria and their possible role in the cell danger response and the upstream 
pathways that cause mitochondrial dysfunction. Development of treatments alleviating 
biological dysfunction will only be possible when the cause of the disease and why affected 
individuals rarely recover is discovered. 
1.6. Aims and Hypotheses  
1.6.1. Aims  
The global goal of this thesis was to determine the molecular changes that occur during post-
exertional malaise, the core symptom of ME/CFS. This will be achieved with the following 
aims: 
1. Identifying how ME/CFS-affected individuals and healthy controls compare in the 
individual steps of mitochondrial energy production over the course of the exercise 
paradigm. 
2. Establishing whether there is an increase in the levels of 8-hydroxyguanosine, a DNA 
biomarker of oxidative stress, over the course of the exercise paradigm, and more 
generally, between ME/CFS-affected individuals and healthy controls. 
3. Examining how the DNA methylomes of ME/CFS individuals change during exercise, 





We hypothesise that: 
1. ME/CFS-affected individuals will have a disturbed mitochondrial function 
compared to healthy controls. 
2. ME/CFS-affected individuals will have higher levels of the biomarker of oxidative 
stress, 8-hydroxyguanosine, compared to healthy controls.  
3. The levels of 8-hydroxyguanosine will increase in ME/CFS individuals over the 
exercise paradigm from the baseline measurement to 24-hour the 48-hour 
measurements. 
4. There will be changes in the DNA methylome of ME/CFS individuals during the 
exercise paradigm.  
5. There will also be a difference between the methylomes of ME/CFS-affected 





2.  M E T H O D S  
 
2.1. Participant Selection  
Five ME/CFS-affected individuals and two healthy controls were recruited through the 
University of Otago’s ME/CFS database. Diagnosis of all ME/CFS-affected individuals was 
confirmed by Dr. Rosmund Vallings using the Canadian Consensus Criteria. Of the five 
ME/CFS individuals, four were females, and one was male. Both control individuals were female. 
Disease severity among affected individuals was determined using the De Paul Symptom 
Questionnaire. The subsequent answers were analysed to ensure that the participants fulfilled 
the ME/CFS International Consensus, Canadian Consensus, and Fukuda criteria for diagnosis 
of ME/CFS. Pre-exercise, all individuals had their resting blood pressure, height, and weight 
recorded. 
For the exercise test itself, a validated incremental cycle ergometer exercise test was used. This was 
designed to peak at cardiac work rates in 8-12 minutes. Here, cardiac work rate refers to the 
product of cardiac output and mean arterial pressure and is used to assess cardiac pumping 
ability. This standardises the level of exertion between ME/CFS-affected individuals and healthy 
controls.  
Participants maintained 60-80 rpm on the cycle ergometer throughout the test and were 
encouraged to participate for as long as possible (until the work rate was achieved). In terms of 
the exercise paradigm, the workload was increased at a rate of 5 watts every 20 seconds. 
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Breath-by-breath gas samples were collected throughout the exercise test via a metabolic cart. 
After reaching the prescribed work rate, participants remained on the cycle ergometer for two to 
five minutes for exercise cool-down. 
During the test on the cycle ergometer, heart rate and rating of perceived exertion were measured 
every minute, and blood pressure was measured manually every two minutes. Following a 20-
minute rest period, cardiac output was measured via a non-invasive rebreathing technique. 
Participants were also then required to cycle for up to five minutes at a set resistance at their 
respiratory exchange ratio. The entire exercise paradigm would then be repeated 24 hours after 
the first exercise test. 
Post-exercise, an exercise recovery questionnaire constructed by Davenport et al., 2010 was 
completed so that participants could report symptoms following exercise. This questionnaire 
was completed by all participants every 24 hours for seven days. 
2.2. Processing Of Blood to Isolate PBMCs  
Four 5mL tubes of blood were taken from each individual before exercising, after the first set of 
exercises (24 hours), and after the second set of exercises (48 hours). Note: extraction of 
peripheral blood mononuclear cells (PBMCs) was performed by senior technician Christina 
Edgar prior to the onset of the project. Blood was diluted in a 1:1: ratio with sterile Phosphate-
buffered saline (PBS), then 4 ml of the diluted blood was layered onto 3 mL of GE Healthcare 
Ficoll-Paque PLUS in a 15 mL falcon tube. This was repeated for the remaining diluted blood. 
The tubes were then spun at 400 xg for 40 minutes at room temperature, with a swing bucket 




FIG 2.1: Depiction of Peripheral Blood Mononuclear Cell (PBMC) extraction.The blood sample was combined 
with 3ml Ficoll-Paque PLUS (GE Healthcare) in a 15 mL falcon tube to isolate PBMCs for mitochondrial study and 
eventual gDNA extraction  
Once centrifugation was complete, the plasma was removed and aliquoted before storing at -80 
° C. The PBMC layer was carefully removed and placed in a falcon tube with three volumes of 
sterile PBS. The PBMC-PBS mixture was mixed gently, then spun at 100 xg for ten minutes at 
room temperature, with a swing bucket rotor and the brake on. The resultant pellet was then 
resuspended in 6 mL of sterile PBS and re-centrifuged at the same conditions. The final pellet 
was resuspended in 6 mL of foetal bovine serum containing 10% DMSO before aliquoting and 
storing overnight in a Mr. Frosty™ Freezing Container at – 80 ° C, then was transferred to liquid 




2.3. Mitochondrial Function Analysis  
2.3.1. Day One 
The mitochondrial function of the live PBMCs extracted during blood sample processing 
was determined using the Agilent Seahorse XF Cell Mito Stress Test Kit. The experiment 
was broken up into two days. Before starting, the Agilent Seahorse XFe/XF Analyzer was 
turned on and programmed for the subsequent day. Then, 2 millilitres (mL) of Cell-Tak-
Sodium Bicarbonate mixture were made using the formula below. 25 microliters (μL) of this 
Cell-Tak-sodium bicarbonate mixture were then added to each well in the Seahorse XF Cell 
Culture Microplate, leaving the four corners of the plate empty.  
Volume of Cell-Tak to add: 
 
𝐹𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ×   𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝐹𝑖𝑛𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒 



















To make up to 2 mL, add: 
 
2 − 1.977 𝑚𝐿 0.1𝑀 𝑆𝑜𝑑𝑖𝑢𝑚 𝑏𝑖𝑐𝑎𝑟𝑏𝑜𝑛𝑎𝑡𝑒 
= 0.023 𝑚𝐿 𝑜𝑟 23 𝜇𝐿 0.1𝑀 𝑆𝑜𝑑𝑖𝑢𝑚 𝑏𝑖𝑐𝑎𝑟𝑏𝑜𝑛𝑎𝑡𝑒 
 
 
The plate was then left at room temperature for 20 minutes; then, each well was washed with 
200 μL of sterile water. The wash was then repeated, and the plate was stored at 4 °C 
overnight. To prepare for the following day, 20 mL of Seahorse XF Calibrant was incubated 
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overnight at 37 °C. 50 mL of Agilent Technologies Seahorse XF base medium (without phenol 
red # 103335-100) was aliquoted and left at 4 °C overnight. 200 μL of sterile water was also 
added to each well in the utility plate, then incubated at 37 °C overnight with an open beaker 
of water to prevent excessive evaporation.  
2.3.2. Day Two  
A 5 mL aliquot of sterile PBS and the 50 mL aliquot of Seahorse XF base medium were first 
incubated at 37 °C during plate loading. The Seahorse XF Cell Culture Microplate loaded 
with Cell-Tak as well as sodium pyruvate were brought to room temperature. Once the 
Seahorse XF base medium had warmed, 0.09 g glucose, 0.5 mL room temperature sodium 
pyruvate, and 0.5 mL L-glutamine were added to it. Using a pH sensor, the media mixture 
was brought to a pH of 7.4, adjusted using 0.1 M NaOH. The media mixture was then 
rewarmed to 37 °C. 
The calibrant and sensor cartridges were removed from 37 °C incubation, and the water in 
the wells was discarded. Each well was then filled with 200 μL of the pre-warmed calibrant 
solution; then, the sensor cartridge was placed back on the plate. The plate-cartridge stack 
was then returned to the 37 ° C incubator for 45-50 minutes. During this time, the PBMCs 
of the patient samples were thawed, then added to 5 mL of respective prewarmed PBS. To 
form a pellet, these tubes were then centrifuged at 400 xg for 10 minutes at 20 °C. During the 
centrifugation step, the supplemented media for the Seahorse XF Cell Mito Stress Test Kit 
was prepared using the table below:  








Diluted mixtures of the compounds were then prepared from the stocks made above , mixing 
thoroughly with long pipette tips in an up and down motion. The exact volumes are shown 
in the table below: 
TABLE 2.2: Volume of Seahorse XF Base Medium and Prepared Stocks To Add For Seahorse Experiment.  
Compound Volume of Stock to Add (µL)  
Volume of Media 
 to Add (mL) 
Oligomycin 300 2.7 
FCCP 600 2.4 
ROT/AA 300 2.7 
2994 µL of Seahorse XF Base Medium was pipetted into a tube, to which DAPI would be 
added just before use.   
Next, the supernatant was removed from the cell pellets, then gently resuspended in 5 mL of 
the pre-warmed (37 ° C) PBS. The PBS-cell mixture was centrifuged at 400 xg for 10 minutes 
at room temperature. During this time, 50 µL of Seahorse XF Base Medium was pipetted 
into the four background wells. Once centrifugation had finished, the pellets were 
resuspended in 500 µL of Seahorse XF Base Medium. The Seahorse XF Cell Culture 
Microplate was then loaded according to the pre-decided plate map, with 50 µL of cell 
suspension being pipetted into the appropriate wells, making sure to pipette alongside the 
of the well not to disturb the Cell-Tak. The plate was then centrifuged at 200 xg for one 
minute with no brake. The plate was then incubated for 25-30 minutes at 37 ° C.  
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During this time, the calibrant and sensor cartridge were removed from 37 ° C incubation. 
Each port was loaded with the appropriate compound. Note: after ports A-C had been 
loaded, 6 µL of DPAI at 5 mg/mL was added to the tube with 2994 µL of Seahorse XF Base 
Medium. 
When the plate was loaded, it was returned to 37 ° C incubation until ready for calibration. 
Once the Seahorse XF Cell Culture Microplate had finished its 25–30-minute incubation, 
130 µL of warmed Seahorse XF Base Medium was pipetted down the side of each well. It was 
then incubated again at 37 ° C for 15 to 25 minutes. 
During this incubation step, the calibration plate loaded with compounds was taken up to 
the Agilent Seahorse XFe/XF Analyzer, and the protocol was begun. Once it had finished 
incubating, the Seahorse XF Cell Culture Microplate replaced the calibration plate and was 
read on the Agilent Seahorse XFe/XF Analyzer. 
When the Agilent Seahorse XFe/XF Analyzer run had finished, the plate was wrapped in 
tinfoil, and the cell count of each cell was determined using a Cytation 5 Cell Imaging Multi-
Mode Reader. 
2.4. Extraction Of gDNA From PBMCs 
gDNA was extracted from PBMC aliquots in two rounds. Several different kits were used to 
extract the gDNA. The Illustra Blood GenomicPrep Mini Spin Kit (GE Healthcare) was used to 
extract gDNA used in RRBS library preparation for the DNA methylome study, and the QIAmp 
DNA Blood MiniKit and Thermo Scientific GeneJET Whole Blood Genomic DNA Purification 
Mini Kit were used to extract the gDNA used in the oxidative stress study.  
30 
 
gDNA extractions were performed according to the manufacturer’s instructions provided, with 
these variations. Samples extracted using the Illustra Blood GenomicPrep Mini Spin Kit were 
vortexed every 2 to 3 minutes during the 10-minute incubation step. Additionally, after washing 
with Wash buffer type 6, the empty column was re-centrifuged in a fresh collection tube for 1 
minute at 11 000 x g to remove any residual wash buffer, which interferes with elution.  
The extractions performed using the Thermo Scientific GeneJET Whole Blood Genomic DNA 
Purification Mini Kit and QIAamp DNA Blood MiniKit were done according to the 
manufacturer’s instructions. As instructions in the QIAamp DNA Blood MiniKit were unclear, 
all centrifuge steps were performed at max speed, as indicated in the manufacturer’s instructions.  
2.5. Oxidative Stress Analysis  
2.5.1. Day One  
This day was necessary to prepare samples for use in the 8-hydroxy 2 deoxyguanosine Elisa 
kit. 1 ug of the extracted gDNA was used per sample, and the input volume was calculated 
using the formula below: 






Where possible, samples were performed in triplicate (requiring a gDNA concentration of 
> 20 ng/µL). The calculated volume of DNA was pipetted into a thin-walled PCR tube, then 
placed on a Thermal Cycler at 95 °C for 3 minutes to separate the DNA into single-strands.  
After this, the tubes were placed on ice to return to room temperature. Once this had 
occurred, the reaction mixture was assembled in the same tube, according to the table below: 
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TABLE 2.3: Volume of Reagents to Add to single-strand DNA. 
Reagent Volume to Add (μL) 
10x Nuclease P1 buffer 5 
Single-strand DNA As calculated in formula above 
Nuclease P1 (diluted 1 in 100) 1 
MilliQ water To bring total reaction volume to 50 μL  
TOTAL 50 μL  
After the reaction mixture had been assembled, it was incubated at 37 °C for 30 minutes on 
the thermal cycler. Once the incubation had finished, 5 μL of 1M ammonium acetate at a pH 
of 7.8 was added. Subsequently, 1 μL of Calf-intestinal alkaline phosphatase (CIP) was added 
to each sample. The mixture was again incubated on the thermal cycler at 37 °C for 10 
minutes. After incubation, the samples were heat-inactivated at 75 °C for 10 minutes in the 
thermal cycler. Upon completing this step, the samples were stored at -20 °C until used in the 
ELISA assay. 
2.5.2. Day Two  
First, the volume of 1x Wash Buffer and 1x 8-hydroxy-2-deoxyguanosine: HRP Conjugate 
Monoclonal Antibody necessary for the number of wells being used was calculated. The 
solutions were then made up to a 1x concentration from the stock solutions provided in 8-
hydroxy 2 deoxyguanosine ELISA Kit (ab201734), using MilliQ water to dilute the 10x 
Wash Buffer stock and 8-hydroxy-2-deoxyguanosine Antibody Diluent to dilute the 100x 8-
hydroxy-2-deoxyguanosine: HRP Conjugate Monoclonal Antibody stock. 
Next, the standards were prepared in duplicate according to manufacturer instructions, 
pipetting 250 μL for each dilution step.  
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The assay procedure was followed according to the manufacturer’s instructions. However, 
the antibody was not added to the standard curve wells as instructed. This means that the 
standards were added, washed, and TMB substrate and stop solution were added, but as no 
antibody was added, the concentration of 8-hydroxy-2-deoxyguanosine could not be 
measured. As the 8-hydroxy-2-deoxyguanosine present in the standards would still be bound 
to the well, the protocol was repeated on just the standard wells. To wash any remaining 
TMB and stop solution from the wells, one wash with wash buffer was performed, though 
the 10x instead of 1x concentration was inadvertently used.  
After the stop solution was added to wells, the absorbance of the wells was measured at 450 
nanometers using a Multiscanner plate reader.  
2.5.3. Analysis  
As per manufacturer instructions, for each sample and standard, the average blank 
absorbance value was subtracted.  
The last standard (S8), containing no 8-hydroxy-2-deoxyguanosine was used as the blank for 
the standards, and its absorbance reading was subtracted from each of the other standards. 
As standards were performed in duplicate, the last standard corresponding to each standard 
set was used to normalise. 
The standard with the higher R2 value was used to calculate the 8-OHdG concentration in 
each sample. This was done by using the absorbance value read on the multiscanner plate 
reader and mapping it to the standard curve, then reading the corresponding concentration.  
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2.6. DNA Methylome Analysis  
2.6.1. Overview of RRBS Library Preparation Protocol  
 
FIG 2.2: Overview of RRBS Library Preparation Protocol 
2.6.2. MspI Digest  
gDNA extractions of 50 and 150 μL were first defrosted from -30 °C storage, vortexed, and 
centrifuged using a microcentrifuge. They were then re-quantified using the Invitrogen 
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Qubit 4 Fluorometer according to the manufacturer’s instructions. The input volume of 
DNA (to equal 500 nanograms (ng) of DNA in the reaction) was calculated using the 
formula below: 






The MspI digest mixture was then assembled in 200 µL PCR tubes according to the table 
below: 
TABLE 2.4: Reaction mixture for MspI digest 










1 As calculated in formula above 
28 µL - volume 
of input DNA 4 8 40 
The resultant assembly was vortexed, then micro-centrifuged to collect the mixture to the 
bottom of the tube. It was then incubated on the BIORAD T100 Thermal Cycler at 37 °C for 16-
20 hours (overnight).  
2.6.3. DNA Purification of MspI Digest  
QIAquick Buffer EB was first incubated at 30 °C on the Eppendorf Thermomixer. 200 µL 
of QIAquick Buffer PB and the 40 µL MspI digest mixture were combined in a QIAquick 
spin column, mixed by inversion, then centrifuged at 13,000 rpm for one minute. Flow-
through was discarded, and the QIAquick column was returned to the same tube. To wash, 
750 µL of QIAquick Buffer PE was added to the spin column and centrifuged at 13,000 rpm 
for one minute. Flow-through was discarded, and the spin column was placed in a new 2 mL 
collection tube. The column was then re-centrifuged for an additional minute to remove the 
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residual liquid. The spin column was then placed in a clean 1.5 mL low-bind Eppendorf tube, 
and 60 µL of the warmed QIAquick Buffer EB was applied directly to the centre of the spin 
column membrane and incubated at room temperature for 5 to 10 minutes. During this time, 
the End Repair Mix for the end repair step was taken out from -20 °C storage to defrost. After 
the 5 to 10-minute incubation, the column was then centrifuged at 13,000 rpm for one 
minute. The 60 µL eluate was then reapplied directly onto the spin column membrane and 
incubated at room temperature for one minute, then centrifuged at 13,000 rpm for one 
minute. 
2.6.4. End Repair  
The 60 µL DNA sample above was combined with 40 µL of End Repair Mix in 200 µL PCR 
tubes. The mixture was then flicked to combine and briefly spun using a microcentrifuge. It 
was then incubated for 30 minutes at 30 °C (with a lid temperature of 100 °C) and held at 4 
°C once complete. 
2.6.5. DNA Purification of End Repair 
The MinElute Buffer EB was returned to a heat block at 30 °C for warming. The 100 µL end-
repair reaction was combined with 500 µL of MinElute Buffer PB in MinElute spin columns. 
These were then mixed by inversion. The samples were then centrifuged at 13,000 rpm for 
one minute, then flow-through was discarded. The columns were placed back in the same 
tubes, and 750 µL of MinElute Buffer PE was added to the column. The mixture was then 
centrifuged at 13,000 rpm for one minute. The columns were transferred to new 2 mL 
collection tubes and re-centrifuged for one minute at 13,000 revolutions per minute (rpm). 
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The columns were then placed in clean 1.5 mL low-bind Eppendorf tubes, and 18 µL of the 
warmed MinElute Buffer EB was pipetted onto the centre of the column membrane. The 
column was incubated for 5 to 10 minutes, during which the A tailing mix was taken out to 
thaw. The spin columns were then centrifuged at 13,000 rpm for one minute. The 18 µL 
eluate was then reapplied to the column membrane and re-centrifuged at 13,000 rpm for one 
minute.  
2.6.6. 3’ End Adenylation  
To begin adenylating the 3’ ends of the DNA, the cleaned sample from above (18 µL) was 
combined with 12.5 µL of A-Tailing mix in a 200 µL PCR tube. This mixture was combined 
by flicking, then briefly spun using a microcentrifuge. The samples were then incubated 
using the protocol below: 
Preheated lid to 100 °C 
37 °C for 30 minutes 
70 °C for 5 minutes 
4 °C for 5 minutes 
Hold at 4 °C 
2.6.7. Adaptor Ligation  
During this time, the adaptors for ligation and a small vial of Resuspension Buffer were taken 
out from -30 °C storage to defrost. Each adaptor corresponded to a specific sample so that 
the unique samples could be identified after sequencing. The adaptors used for each sample 
is displayed below in TABLE 2.5. 
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TABLE 2.5: Adaptors Used in RRBS Library Preparation. 
Sample Name Adaptor Number 
ME016 baseline 1 
ME016 24 hour 2 
ME016 48 hour 3 
ME026 baseline 4 
ME026 24 hour 5 
ME026 48 hour 6 
ME007 baseline 7 
ME007 24 hour 8 
ME007 48 hour 9 
ME024 baseline 10 
ME024 24 hour 11 
ME024 48 hour 12 
C012 baseline 13 
C012 24 hour 14 
C012 48 hour 15 
C036 baseline 16 
C036 24 hour 18 
C036 48 hour 19 
ME028 baseline 20 
ME028 24 hour 21 
ME028 48 hour 22 
The reaction mix for ligation was assembled as below: 
Reagent Volume (μL) 
DNA sample from above 30 
RSB buffer 2.5 
DNA Adaptor Index (diluted 1 in 5 from 
stock) 
2.5 
Ligation Mix 2* 2.5 
TOTAL 37.5 
*The Ligation Mix 2 was only removed from the freezer briefly to be added, then returned.  
The samples were mixed by flicking, then briefly spun using a microcentrifuge. The reaction 
was then carried out on a Bio-Rad T100 thermal cycler using the below protocol: 
Preheated lid to 100 °C 
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30 °C for 11 minutes 
Hold at 4 ° C 
During this time, the stop ligase mix was taken from -30 °C storage to defrost.  
Immediately after the reaction finished, 5 µL of stop ligase mix was added to each tube to 
inactivate ligation. The tubes were mixed by flicking then briefly microcentrifuged. 
2.6.8. DNA Purification of Adaptor-Ligated DNA 
The MinElute Buffer EB was returned to the heat block at 30 °C for warming. The 37.5 µL + 
5 µL stop ligase mixture (42.5 µL) was combined with 212.5 µL of MinElute Buffer PB in 
MinElute spin columns. These were then mixed by inversion. The samples were then 
centrifuged at 13,000 rpm for one minute, then flow-through was discarded. The columns 
were placed back in the same tubes, and 750 µL of MinElute Buffer PE was added to the 
column. The buffer-containing columns were then centrifuged at 13,000 rpm for one 
minute. The columns were transferred to new 2 mL collection tubes and re-centrifuged for 
one minute at 13,000 rpm. The columns were then placed in clean 1.5 mL low-bind 
Eppendorf tubes, and 20 µL of the warmed MinElute Buffer EB was pipetted onto the centre 
of the column membrane. The column was incubated for 5 to 10 minutes. The spin columns 
were then centrifuged at 13,000 rpm for one minute. The 20 µL eluate was then reapplied to 
the column membrane and re-centrifuged at 13,000 rpm for one minute. The DNA was then 
pipetted into 200 µL PCR tubes and stored at -30 °C if not continuing to bisulphite 
conversion immediately.  
2.6.9. Bisulphite Conversion  
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First, the CT conversion reagent was prepared using the EZ-DNA Methylation-direct kit. 
790 µL of M-Solubilization Buffer and 300 µL of M-Dilution Buffer were added to a CT 
Conversion Reagent tube. This was then mixed at room temperature at 1300 rpm for at least 
30 minutes or until the mixture had solubilized (was clear). 160 µL of M-reaction buffer was 
then added to the solution, which was then mixed for a further five minutes.  
To initiate bisulfite conversion, 130 µL of the prepared CT conversion reagent was added to 
the 20 µL sample from above. This was mixed by flicking, then run on the Bio-Rad T100 
thermal cycler using the following protocol: 
37 °C for 15 minutes 
98 °C for 8 minutes 
64 °C for 3 ½ hours 
4 °C for up to 20 hours 
After this, the samples were incubated on an ice tray for 10 minutes. 600 µL of EZ DNA M-
Binding buffer was added to Zymo-Spin IC columns. The bisulphite-converted DNA 
sample was then added to the spin column; the cap was closed and mixed by inversion. The 
samples were centrifuged at 13,000 rpm for one minute, then flow through was discarded. 
100 µL of EZ DNA M-Wash buffer was added to the spin column, after which the samples 
were centrifuged at 13,000 rpm for one minute. 200 µL of EZ DNA M-Desulphonation 
Buffer was added to the spin column. This was then left to stand at room temperature for 15 
to 20 minutes. After around 10 minutes of this incubation, the KAPA HiFi HotStart Uracil 
+ ReadyMix and PCR primer mix were taken out of -30 °C storage to defrost. Once 15-20 
minutes had passed, the samples were centrifuged at 13,000 rpm for one minute. To wash 
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the DNA, 200 µL of M-Wash Buffer was subsequently added to the spin column. The 
samples were then centrifuged at 13,000 for one minute. The wash step was then repeated. 
After centrifuging, the spin columns were placed in clean 1.5 mL low-bind Eppendorf tubes. 
Here, 16 µL of room-temperature EZ DNA M-Elution Buffer was added directly to the spin 
column matrix. The samples were then centrifuged at 13,000 rpm for one minute. The 16 µL 
eluate was then reapplied to the spin column matrix and was once more centrifuged at 13,000 
rpm for one minute.  
2.6.10. Semi-Quantitative PCR  
All PCRs were set up on a dedicated PCR bench to maintain sterility and reduce the risk of 
contamination. A master mix was first assembled using the table below: 
TABLE 2.6: Assembly Details for Semi-Quantitative PCR. 
Where X = the number of samples + 2 
Once the Master Mix was assembled, 22 µL was pipetted into 200 µL PCR tubes with labels 
corresponding to each of the samples at ‘15’ representing that it would undergo 15 PCR cycles. 
After this, 3 µL of bisulphite-converted sample DNA was pipetted into the tube, and the 
mixture was pipetted up and down to combine. The tubes were then briefly 





Volume for X reactions 
KAPA HiFi HotStart Uracil + 
ReadyMix 12.5 12.5 * X
 
TruSeq PCR primer cocktail 3 3 * X 
MilliQ water 6.5 6.5 * X 
TOTAL 22 22 * X 
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labelled with the ‘20’ (20 PCR cycles) and the sample. This would leave an equal volume (12.5 
µL) in the tubes labelled ‘15’. The samples were briefly spun using a microcentrifuge, then 
run using the protocol below: 
TABLE 2.7: Semi-Quantitative PCR Protocol.  
n = number of amplification cycles total desired. 
Condition Temperature (°C) Time (s) # of cycles 
Initial 
denaturation 98 45 1 
Denaturation 98 15 
n - 1 Annealing 60 30 
Extension 72 30 
Final Extension 72 60 1 
Hold 4 ∞  
During the running of the PCR, a 3% NuSieve agarose gel was prepared. This was done by 
combining 200 mL of 0.5x TAE buffer with ethidium bromide* and 6 g of Lonza 50080 
NuSieve GTG agarose and mixing with a magnetic stirrer for 30 minutes at 100 ° C or until 
agarose had almost entirely dissolved (but still appeared cloudy). To fully dissolve the 
agarose, the mixture was microwaved at 2-minute intervals at 50% power with the lid half 
unscrewed until the gel mixture was completely clear.  
*Note: to prepare 0.5x TAE buffer made up of 0.0024% ethidium bromide, the below was 
combined: 
950 mL MilliQ water 
50 mL 10x TAE** 
24 μL Ethidium Bromide 
 
**10x TAE Buffer was made by combining: 
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96.8 g Tris Base 
8.2 g sodium acetate anhydrous 
7.6 g Na2 EDTA 
Adjust pH to 7.9 with glacial acetic acid (takes 30 – 40 mL) 
The gel mixture was left to cool for 5 minutes before pouring into a gel mould. Here it was left 
to set for one hour or until it had fully hardened.  
When the gel had set, and the PCR was complete, the gel was loaded. First, the PCRed samples 
were flick-mixed and then microcentrifuged to collect the DNA to the bottom of the tubes. For 
each sample being loaded, 2μL of XC loading dye were pipetted onto parafilm. 10 μL of sample 
was then combined with a 2 μL droplet, mixed using an up and down pipetting motion. 10 μ
L of this loading dye-sample solution was then loaded into a well. This was repeated for all 
samples. Finally, 7 μL of New England Biolabs Quick-Load Purple Low Molecular Weight DNA 
Ladder was pipetted into a designated well. The gel was then run for 90 minutes at 50 volts. 
Upon completion, it was imaged using the UVIDOC HD6 gel documentation system. 
If the PCR reaction was successful (as shown in FIG 3.11), large-scale PCR was pursued, and the 




2.6.11. Large-Scale PCR 
A similar protocol used to perform the semiquantitative PCR was used for large scale PCR. 
Once again, all PCRs were set up on a dedicated PCR bench to maintain sterility and reduce 
the risk of contamination. A master mix was first assembled using the table below: 
TABLE 2.8: Assembly Details for Large-Scale PCR. 
Where X = the number of samples + 2 
However, unlike the semiquantitative PCR, the samples did not need to be split into 15 and 
20 round aliquots. Once the Master Mix was assembled, 22 µL was pipetted into 200 µL 
PCR. After this, 3 µL of bisulphite-converted sample DNA was pipetted into the tube, and 
the mixture was pipetted up and down to combine. The tubes were then briefly 
microcentrifuged, then run using the protocol below: 
TABLE 2.9: Large-Scale PCR Protocol.  
n = number of amplification cycles total desired. 
Condition Temperature (°C) Time (s) # of cycles 
Initial 
denaturation 98 45 1 
Denaturation 98 15 
n - 1 Annealing 60 30 
Extension 72 30 
Final Extension 72 60 1 






Volume for X reactions 
KAPA HiFi HotStart Uracil + 
ReadyMix 12.5 12.5 * X 
TruSeq PCR primer cocktail 3 3 * X 
MilliQ water 6.5 6.5 * X 




2.6.12.  AMPure Bead Purification Library Quantification 
AMPure beads were used to remove the residual substrate from the PCR reaction and size 
select for adaptor-ligated digested DNA fragments (150-330 bp). The AMPure beads were 
taken from 4 ° C storage and allowed to warm to room temperature 30 minutes before 
purification. 30 minutes later, the beads were thoroughly vortexed. Fresh 70% Ethanol was 
prepared by combining 3 mL absolute ethanol with 1 mL of MilliQ water. As the large-scale 
PCR volume was 25 μL, 15 μL of beads were added to each sample (0.6 x sample volume). 
The bead-sample mixture was then pipetted thoroughly up and down to combine. The 
tubes were then incubated at room temperature for 15 minutes. After this incubation, the 
PCR tubes were placed on a magnetic rack for 5 minutes or until the solution was clear. The 
supernatant, which contained the library, was then pipetted out of the tubes and into a new 
200 μL PCR tube. The old tube containing the beads was then discarded. To the new tubes 
containing the supernatant, 10 μL of new beads were added (0.4 x original sample volume). 
The DNA-bead mixture was then incubated at room temperature for 15 minutes. The tubes 
were then placed on a magnetic rack until the solution was clear (around 5 minutes). The 
supernatant containing adaptor dimers was then discarded.  
Next, 200μL of 70% Ethanol was added to each tube to wash the beads, which now 
contained the large DNA fragments. This was done by keeping the tubes in the magnetic 
rack but rotating the tube so that the bead pellet was forced to move. The beads were then 
allowed to collect once more; then, the ethanol was removed. This wash step was then 
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repeated. Extra care was taken to remove all of the ethanol on the second wash step. The lids 
of tubes were left open to evaporate the remaining ethanol. When the bead pellet gained a 
matte appearance and started to form small cracks, 20 μL of elution buffer was added, 
making sure to resuspend the beads. The solution was then incubated at room temperature 
of the magnetic rack for a minimum of 15 minutes. After this incubation, the PCR tubes were 
placed on the magnetic rack until the solution was clear (around 5 minutes). From here, 18 
μL of the supernatant could be extracted from the tube and pipetted to a new PCR tube. 
This was the final RRBS library for the sample.  
2.6.13. Bioanalyzer High Sensitivity DNA Assay 
So that the bioanalyzer could be performed, the RRBS library must be quantified. This was 
done using the Qubit 1x dsDNA High Sensitivity kit according to manufacturer 
instructions. 
To see the fragment size distribution of the library, a bioanalyzer run was performed 
according to manufacturer instructions. It is important to note that all libraries were diluted 
to <10 nM using MilliQ water before being run on the bioanalyzer.  
If the resultant bioanalyzer data showed a high amount of DNA fragments at 150 -330 bp, 




2.6.14. Data Analysis 
2.6.14.1. PREPARING SEQUENCING FOR ANALYSIS  
Once sequencing was completed, the raw fastq output files were processed by Dr. Euan 
Rodger of the University of Otago Department of Pathology, who removed any excess 
adaptor sequences from the dataset. The files were aligned to the human genome using 
Bismark. The resultant BAM file was analysed using the Differential Methylation 
Analysis Program (DMAP) developed by Peter Stockwell of The Department of 
Pathology, Otago90. This program selects fragments that have a MspI cleavage site and 
are 40-220 bp in length. The number of methylated and unmethylated CpG sites are 
determined, which allows the various fragment reads to be matched based on CpG 
position and methylation.  Finally, it calculates the number of reads per fragment 
(coverage) and quantifies the methylation of each fragment to produce a F2t10 value for 
each sample. This is the number of fragments with at least 2 CpGs and a coverage of 10 
or more reads.  
2.6.14.2. ANALYSIS 
The raw p-value for each fragment was calculated using a Fisher’s Exact test performed 
by Dr. Rodger. From this, the FDR-adjusted p-value was calculated using the Benjamini-
Hochberg correction in Microsoft Excel version 2107. Each fragment’s absolute 
methylation difference between the two time points was calculated by minusing the 24-
hour or 48-hour value (between zero and 1) from the baseline value.   
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The location of each fragment based on CpG location was assigned as “intergenic”, 
“promoter”, “exon”, “intron”, “boundary”, or “other”. A table summarising the 
assignment conditions is shown below: 
TABLE 2.10: Assignment Conditions for Genomic Location of Fragment.  
Here, the “Intergenic” and “Promoter” variables were labelled based on the value in the “Enddist” column, and the 
“Intron”, “Exon”, “Boundary” and “Other” variables were labelled based on the content in the “CpG_location” 
column. 
Label Defined as 
Intergenic Enddist value > 500 (meaning <-500 from the TSS) 
Promoter Enddist value < 500 AND > -1500 (meaning >-500 AND < +1500 bp 
from the TSS) 
Intron on_intron or intron_internal 
Exon on_exon or exon_internal 
Boundary exon_intron_boundary or intron_exon_boundary 
Other Values that did not fulfil any of the above criteria (extreme negative 
values) 
 
Volcano plots were constructed for both timepoint comparisons using Microsoft 
Excel version 2107, comparing the absolute methylation difference and its 
corresponding -log10 transformed p-value (calculated using Fisher’s Exact Test). A 
significance threshold of p <0.05 (-log10 p-value of 1.30102999566) was used. 
“Differential methylation” was defined as having an absolute methylation difference 
of < -0.15 (hypomethylated) or > 0.15 (hypermethylated). 
Fragments that were differentially methylated and remained significant after 
multiple testing correction, that were also located in the promoter were selected. 
Fragments that had an FDR-adjusted p-value of <0.05 and not equal to zero were 
classified as significant. Differentially hypomethylated fragments were defined as 
having an absolute methylation difference of less than -0.15. Differentially 
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hypermethylated fragments were defined as having an absolute methylation 
difference of greater than 0.15.  







3 .  R E S U L T S  
 
3.1. Mitochondrial Function Analysis  
To determine whether mitochondrial function was decreased between ME/CFS patients and 
controls, as well as whether it decreased during PEM, a Mitochondrial Stress Test was performed 
using a Seahorse XF Analyzer. This is designed to mimic the subunits of the electron transport 
chain and measures the oxygen consumption rate as a measure of mitochondrial function. These 
results also allow us to determine individual markers of mitochondrial function (see FIG 3.1, 
panel “A”).  
The results of this experiment showed that the five ME/CFS individuals, in fact, had higher rates 
of oxygen consumption, on average, compared to the two controls (see FIG 3.1). However, after 
the onset of exercise, ME/CFS mitochondrial function decreased dramatically in three subjects 
(see FIG 3.1, panels B, C & E), suggesting that exercise in ME/CFS individuals causes 
mitochondrial function to decrease. Two ME/CFS patients did not show this decrease. One 
control individual (C012) also displayed a decrease, however, but it should be noted that each 






FIG 3.1: Seahorse XF Cell Mito Stress Test Profiles.  
A= Seahorse XF Cell Mito Stress Test schematic(adapted from Gotoh, et al. 92), depicting individual features of respiration, to be calculated using each individual’s oxidative consumption rate. B-D = Seahorse 
XF Cell Mito Stress Test Profiles comparing oxygen consumption rate (OCR) (pmol/min) as a measure of mitochondrial respiration, over time (minutes), showing before exercise sample (yellow), after the 
first exercise (24 h, blue), and after the second exercise (48 h, green). Circle and triangle points show values from two sets of replicates. E-H = Seahorse XF Cell Mito Stress Test Profiles comparing Oxygen 
consumption rate (pmol/min) over time (min), showing before exercise sample (yellow), after the first exercise (24 h, blue), and after the second exercise (48 h, green).  
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The results from individual mitochondrial features show that non-mitochondrial respiration is 
much higher in ME/CFS subjects on average, compared to controls, though decreases after the 
first exercise, whereas the controls remain low throughout. (Fig 3.2, panel “A”). One intriguing 
observation is that ATP production in response to exercise is different between ME/CFS 
individuals and controls, with ATP production increasing in controls, yet decreasing among 
ME/CFS individuals, then returning to a near “baseline” level. In ME/CFS subjects, individual 
components of mitochondrial respiration all decrease in response to exercise, whereas it does not 
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FIG 3.2: Differences in Mitochondrial Function Markers in ME/CFS Individuals vs Controls.These were calculated using each individuals’ 
OCR in pmol/min. Values were averaged to produce overall values for each time point, where 0 = before exercise sample, 24 = from after the first 
exercise = 48 = from after the second exercise. A =Non-Mitochondrial Respiration, B = Basal Respiration, C = ATP Production, D = Proton Leak, E = 
Maximal Respiration (maximum rate of respiration the cell can achieve), F = Spare Respiratory Capacity (how close the cell is to respiring to its 
theoretical maximum), G = Coupling Efficiency (percentage of mitochondrial respiration linked to ATP synthesis relative to the amount of proton 











A key finding was that ATP production decreased after exercise in ME/CFS affected individuals 
yet increased after exercise in controls. Some individuals displayed this trend more noticeably 
than others. Particularly of interest are the profiles of ME016 and, to a lesser extent, ME007, and 
ME024, who display this trend more dramatically (see Fig 3.3). However, this was not 
statistically significant when examining differences at the subject level (Fig 3.3).  
FIG 3.3: Differences in The Levels of ATP Production Per Individual, Over Time.  
ATP Production was calculated from each individuals’ oxygen consumption rate (pmol/min). Where individuals had replicate data 
(ME016, ME026, and C012), values were averaged. ME/CFS-affected individuals are shown in yellow (left) and controls in blue (right). 
Note, different y-axes are used for each individual, as the trend of interest is how individuals change overtime, within themselves, rather 




Nonetheless, we can conclude that oxygen consumption rate was higher among ME/CFS 
individuals compared to controls, and this decreased substantially after exercising to their peak 
work rate.  
3.2. Oxidative Stress Analysis  
To ascertain the quality and quantity of the gDNA samples which would be used for the 
oxidative stress study, they were read on a NanoDrop spectrophotometer. Results of this are 




















50 81.1 1.5 1.0 
6.0 
150 13.1 1.7 1.7 
24 h 
50 45.3 1.7 0.9 
2.9 
150 4.5 1.9 5.8 
48 h 
50 58.9 1.7 1.3 
8.6 
150 37.7 1.5 1.0 
ME026 
Baseline 
50 38.1 1.7 1.1 
5.3 
150 22.3 1.8 1.5 
24 h 
50 23.1 1.8 1.1 
2.6 
150 9.5 1.6 1.2 
48 h 
50 47.2 1.5 0.7 
3.8 
150 9.4 1.5 1.3 
C012 
Baseline 
50 14.7 1.7 0.8 
1.3 
150 3.6 1.7 1.1 
24 h 
50 80.9 1.4 0.6 
4.4 
150 2.5 3.2 3.0 
48 h 
50 21.4 1.4 0.6 
2.9 
150 12.4 1.8 0.6 
ME007 
Baseline 
50 60.2 1.8 1.5 
4.7 
150 11.0 1.7 2.6 
24 h 
50 40.8 1.7 1.4 
3.8 
150 11.6 1.7 1.5 
48 h 
50 35.7 1.5 1.3 
3.8 
150 13.5 1.8 2.3 
ME024 
Baseline 
50 18.0 1.6 0.7 
1.9 
150 6.5 1.7 1.5 
24 h 
50 18.0 1.6 0.7 
2.0 
150 7.0 1.9 1.3 
48 h 
50 19.3 1.6 0.8 
2.2 
150 7.9 1.7 2.2 
ME028 
Baseline 
50 12.1 1.6 0.9 
1.3 
150 4.7 1.4 1.1 
24 h 
50 9.7 1.6 0.4 
1.0 
150 3.6 1.7 0.5 
48 h 
50 11.4 1.6 0.5 
2.0 
150 9.3 1.7 1.9 
C036 
Baseline 
50 34.0 1.6 1.4 
2.4 
150 4.8 1.7 1.2 
24 h 50 26.6 1.6 0.8 2.5 
 150 7.6 1.6 2.3  
48 h 50 23.3 1.7 1.6 1.4 
 150 1.7 1.2 -0.2  
TABLE 3.1: Quality and quantity of gDNA used in oxidative stress experiments.  
Data was gathered using a NanoDrop spectrophotometer. Samples are segregated by the time the blood sample was collected, where “Baseline” = before first 
exercise, “24 h” = after the first exercise, and “48 h” = after the second exercise. Four gDNA extractions were performed for each sample; each sample’s first 
extraction is displayed in the table above. The remaining three extractions are not shown for simplicity but had similar values. The “Fraction” column reflects the 
values for elution fraction (50 µL or 150 µL). “Total Yield” was calculated by multiplying each fraction’s gDNA concentration (ng/μL) by the elution volume (50 
or 150 μL), then converted to μg by dividing by 1000.   
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To determine whether ME/CFS individuals had a higher level of oxidative stress than controls, 
an 8-OHdG ELISA assay was performed.  
 
FIG 3.4: Comparison of Guanosine and 8-OHdG Structures. Guanosine (left), 8-Hydroxy-2'-deoxyguanosine (right). Courtesy 
of the National Center for Biotechnology Information 93, National Center for Biotechnology Information 94.  
8-OHdG is a commonly used biomarker of oxidative stress, occurring when increased reactive 
oxygen and nitrogen species oxidise a guanosine base which can cause G → T and A → C 
substitutions unless repaired prior to DNA replication 95. 
The concentration of 8-OHdG in the study samples was calculated using the standard curve 
pictured below (FIG 3.5). The R2 value is relatively high, providing a reliable basis for predicting 








The results of this experiment show that ME/CFS individuals show almost no difference in the 
levels of 8-OHdG when compared to controls, with a mean difference in 8-OHdG 
concentration, overall, of 0.61 ng/μL. Furthermore, there is no definitive trend in 8-OHdG 
concentrations in both cohorts over time (see FIG 3.6). Importantly, there was little difference 
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FIG 3.5: Standard Curve of 8-OHdG for oxidative stress assay.  
Measuring the absorbance of samples at 450 nm with known concentrations to allow calculation of the concentration of 8-hydroxy 2 
deoxyguanosine (8-OHdG) in each sample (ng/μL).  
 
FIG 3.6: Concentration of 8-OHdG in ME/CFS Individuals vs Controls, over time.  
Displays concentration of 8-OHdG (ng/μL) before exercise (0), after the first exercise (24), and after the second exercise (48). Left 






































Some individuals (ME026, ME028) trend upwards after exercise, though this is also observed in 
one control (C036) (FIG 3.8). Whilst the magnitude of this difference is slight, the increase may 
be a dramatic difference when used as a biomarker.  
These results suggest that 8-OHdG levels, as a biomarker of oxidative stress, do not increase in 
response to exercise in some ME/CFS individuals that exercised to their peak work rate, nor is 
there a difference in its concentration between ME/CFS-affected individuals and controls.  
  
FIG 3.8: Individual Differences in 
The Concentration Of 8-OHdG in 
ME/CFS Individuals vs Controls, 
Over Time. 
Note: the y-axes vary across individuals 
to allow visualization of differences 
within an individual, though the 





3.3. DNA Methylome Analysis  
To determine whether the DNA methylome of ME/CFS-affected individuals changed during 
exercise, gDNA was first extracted from the PBMCs extracted in section 2.2. To ascertain the 
quality and quantity of the gDNA, it was read on a NanoDrop spectrophotometer. Results of 















Baseline 50 76.9 1.91 1.19 150 20.2 2.37 0.73 
24 h 50 21.5 2.30 0.75 150 4.5 5.77 0.21 
48 h 50 24.0 2.35 0.6 150 7.0 4.17 0.28 
ME026 
Baseline 50 35.9 2.07 1.21 150 7.5 7.21 0.64 
24 h 50 26.7 2.07 0.8 
150 5.1 6.12 0.24 
48 h 50 35.8 1.67 0.34 150 10.4 2.57 0.24 
C012 
Baseline 50 41.7 2.05 1.13 150 9.2 2.96 0.46 
24 hrs 50 41.6 1.99 0.61 150 13.8 2.52 0.41 
48 hrs 50 31.2 1.92 0.65 150 9.6 2.40 0.36 
ME007 
Baseline 50 42.7 1.90 0.73 150 9.0 3.06 0.38 
24 h 50 53.0 2.12 1.32 150 20.9 2.39 0.94 
48 h 50 49.0 1.99 1.08 150 14.5 2.54 0.63 
ME024 
Baseline 50 49.1 1.78 0.68 150 14.7 2.63 0.59 
24 h 50 22.7 1.82 0.28 150 4.5 -20.66 0.18 
48 h 50 25.9 2.04 0.7 150 7.6 3.98 0.32 
ME028 
Baseline 50 47.4 1.97 0.35 150 20.1 1.95 0.37 
24 h 50 44.5 1.89 0.28 150 18.5 2.05 0.51 
48 h 50 51.5 1.90 1.05 150 19.9 1.89 0.54 
C036 
Baseline 50 64.5 1.79 0.73 150 16.5 2.37 0.62 
24 h 50 69.2 1.91 0.48 150 26.0 2.06 0.42 
48 hrs 50 43.3 1.65 0.55  150 14.4 1.93 0.41 
 
TABLE 3.2: Quality and quantity of gDNA used in DNA methylome experiments. Data was gathered using a NanoDrop 
spectrophotometer. Samples are segregated by the time the blood sample was collected, where “Baseline” = before first exercise, “24 h” = 





The DNA was considered to have a sufficient concentration (exceeded 25 ng/µL) (see TABLE 
3.2 ). The average 260/280 ratio in the 50 µL fraction was close to the accepted value of “pure” 
DNA of 1.8, though much higher in the 150 µL fraction, which was expected96. The 260/230 ratio 
was lower than the range expected for “pure DNA” (2.0-2.2) across both elution fractions. 
To confirm that the extracted gDNA was not degraded, which would affect the library 
preparation, the gDNA was run on an agarose gel (see FIG 3.9). The band was clean, indicating 
un-degraded DNA, which would be more spread.  
 
FIG 3.9: Example of Un-degraded gDNA. “L” lane shows Lambda DNA marker that was labelled radioactively with T4 
Polynucleotide Kinase. “1” = gDNA sample (ME026 Baseline 50 μL fraction as seen in TABLE 3.2).  
3.3.1. RRBS Library Preparation  
Provided that the gDNA was of sufficient quality and was not degraded, RRBS library 
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FIG 3.10: Depiction of RRBS library preparation.  




To determine the number of cycles of large-scale PCR that would minimise adaptor dimer and 
maximise the number of amplified fragments, semi-quantitative PCR was performed. The 
product of this was then observed using gel electrophoresis. This step was also necessary to 
confirm that amplification had occurred. Nineteen out of twenty-one samples showed 
successful amplification. A representative gel image is shown below in FIG 3.11. 
 
FIG 3.11: Successful Amplification of Digested DNA.The image shows amplified DNA after semi-quantitative PCR 
during the RRBS library preparation. “15” and “20” rounds correspond to the number of amplification cycles those samples 
experienced during PCR. bp = length of DNA in base pairs. L = Low Molecular Weight DNA Ladder, 1 = ME016 Baseline 
sample, 2 = ME016 24-hour sample, 3 = ME016 48-hour sample, and 4= ME026 baseline sample. “-ve” = negative control 
containing same PCR mixture as described in TABLE 2.6, except MilliQ water is used in place of digested DNA.   
The desired DNA product is shown as a smear from around 150 to 330 bp. The number of 
amplification cycles chosen based on the semi-quantitative PCR gels ranged from 15 to 20 cycles. 
Successful amplification of all samples except ME028 24- and 48-hour samples was achieved. The 

















FIG 3.12: Unsuccessful Amplification of Digested DNA.The image shows un-amplified DNA after semi-quantitative 
PCR during the RRBS library preparation. “15” and “20” rounds correspond to the number of amplification cycles those 
samples experienced during PCR. bp = length of DNA in base pairs. L = Low Molecular Weight DNA Ladder, 4 = ME028 
24-hour sample, 5 = ME028 48-hour sample. “-ve” = negative control containing same PCR mixture as described in TABLE 
2.6, Section 2.6.10, except MilliQ water is used in place of digested DNA.  Bands at ~125 bp are adaptor dimers.  
Nonetheless, library preparation was continued on the remaining 19 samples. To confirm that 
the library contained fragments of the desired length (40-220 bp), samples were read using a 
















FIG 3.13: Bioanalyzer plots of RRBS libraries sent for Sequencing.Desired bead-cleaned, adaptor-ligated 
fragments for sequencing are located between 150 and 330 bp. Sample 1 = ME016 baseline, Sample 2 = ME016 24 h, 
Sample 3 = ME016 48 h, Sample 4 = ME026 baseline, Sample 5 = ME026 24 h, Sample 6 = ME026 48 h, Sample 7 = 
ME007 baseline, Sample 8 = ME007 24 h, Sample 9 = ME007 48 h, Sample 10 = ME024 baseline. Peaks at 35 and 
10380 bp allow for the calculation of fragment size. Y-axis shows the “Formula-Units” measuring the number of DNA 
fragments that correspond to that length. Panel “B” shows the gel image produced during the bioanalyzer run. The 
magenta box indicates the range of desired fragment lengths. 
All samples display fragments present in the desired range (40 - 220 bp), which after adaptor 
ligation correlates to fragments of 150-330 bp. Samples 1-4, however, show three distinct peaks. 
Samples 5 through 10 show a smoother fragment spread and, therefore, more effective MspI 
digestion. However, overall, the bioanalyzer report showed that the DNA was of sufficient 
quality to be submitted for sequencing.  
Unfortunately, in the bioanalyzer run on the remaining nine samples, the marker ran 







determined. Limitations induced by the COVID-19 lockdown prevented the repetition of the 
experiment, so the first ten samples only were sent away for sequencing.  
3.3.2. Data Analysis  
Sequencing was successful in all samples (1-10), to a varying level of quality (see TABLE 3.3). 
Despite this, the F2t10, which is the number of fragments containing at least 2 CpGs and a 
coverage of 10 or more reads, was insufficient to perform a methylome analysis in 7/10 samples. 
However, the F2t10 in ME016’s samples (Baseline, 24 h and 48 h) was sufficient. Therefore, 
methylome analysis was pursued in only one individual, with a focus on how the DNA 
methylome changes during PEM in ME/CFS individuals, rather than also comparing this to 
controls. 
TABLE 3.3: Features of Samples After Sequencing.  
F2t10 displays the number of fragments with at least 2 CpGs and coverage of 10 or more reads. Mapping Efficiency denotes 
the percentage of fragments that were able to be aligned to the human genome. C methylated in CpG context shows the 
percentage of methylated CpG sites in the sample.  
  Sample_ID Mapping efficiency (%) 
C methylated in CpG 
context (%) F2t10 
ME016 
Baseline 70.3 49.3 507370 
ME016 24 h 67.3 46.1 475731 
ME016 48 h 67.0 50.4 359611 
ME026 
Baseline 67.4 50.2 120 
ME026 24 h 71.9 70.0 41599 
ME026 48 h 70.1 54.2 75 
ME007 
Baseline 63.1 66.6 76 
ME007 24 h 66.7 68.4 253116 
ME007 48 h 64.7 71.6 67 
ME024 




3.3.3. Whole Genome Changes  
There were many differentially methylated (DM) fragments across the entire genome. FIG 3.14 
displays each fragment’s absolute methylation difference (24 or 48 h methylation value minus 
baseline methylation value) against its -log10 p-value. This suggests that ME/CFS-affected 







FIG 3.14: Volcano Plots Displaying Differential Methylation Between Baseline and 24 h Samples, and Baseline and 48 h Samples, Across Entire 
Genome.  
Left panels show all fragments that are differentially methylated, with hypomethylation in blue and hypermethylation in red. Right panels show all fragments 
with statistically significant methylation data (shown in orange). Fragments with “Differential Methylation” were defined as having an absolute methylation 
difference (AMD) of <-15% (hypomethylated), or >15% (hypermethylation). This was calculated by subtracting either the 24- or 48-hour methylation value 
from the baseline methylation value. Significance was defined as having a p-value of 0.05 (-log10 p-value of <1.30102999566). The -log10 p-value was calculated 
by -log10 transforming the p-value calculated using the Fisher’s Exact Test. Some of the most significantly differentially methylated genes are labelled. Note, 
the y-axes in the two comparisons are different to allow better visualisation of the separation of data points, as the baseline vs 48-hour comparison has data 




For each time point comparison, the top five most significantly differentially methylated genes 
across the entire genome were identified (TABLE 3.4 & TABLE 3.5).  
TABLE 3.4: Top Five Significantly Differentially Methylated Genes Between Baseline and 24-Hour Samples 
Across Entire Genome.  
Significance is defined as having an FDR-adjusted p-value of <0.05. Differential Methylation is defined as having an 
absolute methylation difference of <-0.15 (hypomethylated) or >0.15 (hypermethylated). “Intergenic” is defined as having an 
Enddist value >500 (meaning <-500 from the Transcription Start Site (TSS)). “Promoter” is defined as having an Enddist 
value <500 and >--1500 (meaning >-500 and <+1500 bp from the TSS). 
Baseline vs 24-hour Comparison 
GeneID 
Methylation 
Direction CpG_location Methylation_Difference 
FLT3LG Hyper exon 0.4516 
PTCHD3 Hypo promoter -0.4154 
KLF14 Hyper intergenic 0.3881 
RP1-
139D8.6 
Hypo intergenic -0.3845 
FOXF1 Hypo intergenic -0.3831 
TABLE 3.5: Top Five Significantly Differentially Methylated Genes Between Baseline and 48-Hour Samples 
Across Entire Genome.  
Significance is defined as having an FDR-adjusted p-value of <0.05. Differential Methylation is defined as having an 
absolute methylation difference of <-0.15 (hypomethylated) or >0.15 (hypermethylated). “Intergenic” is defined as having an 
Enddist value >500 (meaning <-500 from the Transcription Start Site (TSS)).  
Baseline vs 48-hour Comparison 
GeneID Methylation Direction CpG_location Methylation_Difference 
POU3F3 Hyper intergenic 0.5083 
ADAMTS10 Hyper intergenic 0.477 
LATS2 Hyper exon 0.4429 
RGS14 Hyper boundary 0.4393 
ARC Hypo intergenic -0.4393 
Pathways involved include the nervous system (ARC, POU3F3), immune function (ARC, 
FLT3LG, KLF14), metabolism (ADAMTS10, KLF14), DNA damage (LATS2), sperm and G-
Protein Coupled Receptor signalling (LATS2, RGS14). The remaining genes’ functions, 
however, had not yet been characterised (FOXF1 & RP1-139D8.6), or did not seem relevant as 
the individual studied was female (PTCHD3).  
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However, for the purposes of this project, promoter-based changes were focused on as these are 
understood to affect gene expression the most. The genome-wide changes will instead be further 
analysed upon completion of the thesis.  
3.3.4. Promoter-Located Changes 
To determine which gene promoters were differentially methylated between before and after 
exercise, samples were selected for significance, and those that were differentially methylated were 
identified. Around 1% of the fragments in the DNA methylome were significantly differentially 
methylated (766 fragments in the baseline vs 24-hour comparison, versus 989 in the baseline vs 
48-hour comparison) (see section 3.3.4). These were predominantly found in the intron and 
intergenic regions, though around 5% of said fragments lay in the promoter regions of genes (FIG 
3.15). This is comparable to a study on a similar matter97, though the proportion found in the 





The promoter located genes that were significantly differentially methylated in either the baseline vs 
24-hour comparison or the baseline vs 48-comparison were identified. These are listed below in TABLE 
3.6. 
  
FIG 3.15: Genomic Location of the CpGs in Significantly Differentially Methylated Fragments in ME016 Baseline vs 24 h And 
Baseline vs 48 h Comparisons.  
The “Promoter” region was defined as between -1500 and +500 bp from the Transcription Start Site (TSS). Intergenic regions were defined as 
<-1500 bp from the TSS. Significance was defined as having an FDR-adjusted p-value of <0.05, not including zero. Differential methylation 
was defined as having an absolute methylation difference of <-0.15 (hypomethylation) or >0.15 (hypermethylation) 
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TABLE 3.6: All Promoter-Located Genes That Were Significantly Differentially Methylated in Either B v 24 or B v 48 h.   
Baseline vs 24-hour comparison is shown on the left, baseline vs 48-hour comparison is shown on the right. Hypermethylated is 
defined as having an absolute methylation difference (AMD) of >15%. Hypomethylation is defined as having an AMD of <-15%. 
Genes are shown from most differentially methylated to least (but still statistically significant). Significance is defined as having an 
FDR-adjusted p-value of <0.05. Genes that are hypermethylated across all time points are highlighted in red. Genes that are 
hypomethylated across all time points are highlighted in blue. AMD is calculated by minusing the 24-hour or 48-hour sample from 
the baseline sample to see the change in methylation.  
B v 24 h  B v 48 h 
Gene Name AMD (%)  Gene Name AMD (%) 
Hypermethylated  Hypermethylated 
HADHB 29.4  KCNJ12 30.4 
DCAF12L2 24.5  CENPF 27.1 
ZNF449 20.4  CXorf24 25.9 
CYP7B1 18.8  POU3F4 23.0 
CCDC144NL 18.2  ARX 22.5 
AC134312.1 17.6  PABPC4 22.3 
GK 17.5  TRIM16L 21.9 
TCP10L2 17.3  TRIM59 21.4 
IL13RA1 16.6  C20orf177 20.5 
CXorf24 16.5  NEIL2 20.1 
NSD1 16.4  TMEM47 19.1 
KCNJ12 16.1  AKR1B15 18.7 
MAP3K15 15.2  GPR25 18.7 
Hypomethylated  MAOB 17.5 
PTCHD3 -41.5  GABRE 17.4 
NCL -24.2  FHL1 17.3 
SOX3 -23.3  NSD1 16.9 
ANKRD58 -22.3  ATP2B3 16.8 
ZIM2 -20.5  DRD5 16.8 
LRCH3 -20.4  ZDHHC9 16.6 
IER3IP1 -20.4  PDZD4 16.5 
APCDD1 -19.9  ZNF135 16.4 
BEX2 -19.7  EXOC3L2 15.7 
ERCC6L -18.9  AC003682.1 15.4 
CHST7 -18.4  MPDU1 15.3 
FAM123B -18.1  SORD 15.2 
CXorf24 -17.5  SCML2 15.0 
KCNJ12 -17.0  Hypomethylated 
CERS2 -16.8  SUSD3 -33.6 
CCDC144NL -16.7  NPR2 -32.1 
UPP1 -16.3  EMILIN1 -30.1 
GK5 -16.3  GTF2A2 -29.5 
EMILIN1 -16.2  POU5F1 -29.4 
POLR1B -16.1  POU3F4 -27.2 
SLC25A14 -15.5  SOX3 -25.6 
73 
 
   ADRA1B -24.3 
   TM2D3 -21.9 
   LDOC1 -21.1 
   STMN1 -20.3 
   NPR2 -19.5 
   INSRR -18.6 
   ZNF513 -18.2 
   RNF212 -18.2 
   NUDT11 -18.1 
   ARMCX1 -18.1 
   PIWIL1 -17.4 
   RBMX -16.9 
   C3orf55 -16.8 
   RRAGB -16.7 
   CETN2 -16.7 
   PGRMC1 -16.6 
   IRAK2 -16.5 
   SETDB1 -16.2 
   SLC25A14 -16.1 
   LDHAL6A -16.1 
   ANKRD30BL -15.5 
More genes were significantly differentially methylated in the baseline versus 48-hour 
comparison than the baseline vs 24-hour comparison. Six genes were significantly differentially 
methylated across both time points, three hypermethylated and three hypomethylated. 
Descriptions of these genes are listed below in TABLE 3.7. 
TABLE 3.7: Promoter-Located Genes Significantly Differentially Methylated Across Entire Exercise 
Paradigm. 
Hyper = hypermethylated, Hypo = hypomethylated. Descriptions are adapted from genecards.org98. 
Gene Name Description Direction of methylation 
CXorf24 (aka 
LINC01560) Long Intergenic Non-Protein Coding RNA 1560. Uncharacterised. Hyper 
EMILIN1 Elastin Microfibril Interfacer 1. Involved in the development of elastic tissues such as blood vessels, dermis, heart and lung. Hypo 
KCNJ12 
Potassium Inwardly Rectifying Channel Subfamily J Member 12. 
Encodes a K+ channel predicted to be involved in synapses and 





Nuclear Receptor Binding SET Domain Protein 1. Enhances 
androgen receptor transactivation. Also involved in chromatin 
organisation and metabolism. 
Hyper 
SLC25A14 Solute Carrier Family 25 Member 14. Involved in brain mitochondrial proton leak Hypo 
SOX3 
SRY-Box Transcription Factor 3. Transcription factor required 
during formation of the HPA-axis. Suppresses neuronal 
differentiation. 
Hypo 
To determine whether the products of these significantly differentially methylated genes interact, a STRING pathway analysis was 
performed (see  
FIG 3.16).   
 
FIG 3.16: STRING Pathway of Significantly Differentially Methylated Promoter-Located Genes  
Shows genes in which fragments were mapped to the promoter region of a gene and significantly differentially methylated. Significance 
was defined as having an FDR-adjusted P-value of <0.05. Fragments classified as “differentially methylated” had an absolute 
methylation difference (AMD) of <-15% (hypomethylated) or >15% (hypermethylated). Resultant figures are courtesy of the STRING 
website 91. A= significantly differentially hypermethylated genes across the baseline vs 24-hour comparison, B = significantly 
differentially hypomethylated genes across the baseline vs 24-hour comparison, C= significantly differentially hypermethylated genes 
B vs 24, Hypermethylated B vs 24, Hypomethylated 







across the baseline vs 48-hour comparison, D = significantly differentially hypomethylated genes across the baseline vs 48-hour 
comparison. 
These results suggest a strong network of interactions, especially in the baseline vs 48-hour 
comparison. The interactions implicate mitochondria and, more widely, metabolism during 
PEM (FIG 3.16, panel “B” and “C”). It adds to evidence of SOX3’s involvement in PEM as it is 
found to interact with other differentially methylated genes’ products in both sets of 
comparisons. There are many interactions between gene products involved in the nervous system 
(ARX, POU3F4, DRD5, SOX3, and SLC25A14).  
Whilst we cannot confirm whether there is a difference in the methylomes of ME/CFS-affected 
individuals and controls during exercise, given that only 1 subject revealed data that could be 





4.  D I S C U S S I O N  
 
4.1. Summary 
ME/CFS is a debilitating and often life-long condition, resulting in severe symptoms that affect 
the individual’s ability to perform even everyday tasks. Post-Exertional Malaise (PEM), a key 
symptom of the disease, arises in response to emotional, physical, or mental exertion and appears 
more often in ME/CFS than in any other condition 19, 99, 100.  It is for this reason that this thesis 
endeavoured to determine the molecular changes during PEM to better understand the 
molecular basis of ME/CFS. In a cohort of 5 ME/CFS subjects and two controls, it inspected 
whether mitochondrial function was disturbed after exercise in those with ME/CFS compared 
to controls, whether the levels of 8-hydroxyguanosine, a DNA biomarker of oxidative stress, 
increased over the course of the exercise paradigm, as well as between ME/CFS-affected 
individuals and healthy controls. In one ME/CFS-affected individual, it established whether the 
DNA methylome changed during exercise and how the differentially methylated genes may 
explain ME/CFS symptomology.  
4.2. Mitochondrial Function 
As mitochondrial dysfunction has been heavily linked to ME/CFS, we first sought to identify 
whether ME/CFS-affected individuals and healthy controls differed in their mitochondrial 
function, and more specifically, the individual steps of mitochondrial energy production during 
the exercise paradigm.   
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ME/CFS individuals did show a different trend in mitochondrial function compared to controls. 
The tendency of the oxygen consumption rate, as a measure of mitochondrial function, to 
decrease after the onset of exercise further strengthens the hypothesis that the fatigue experienced 
by ME/CFS patients is due to an impairment of mitochondrial function. It also provides an 
explanation for why Coenzyme Q prescription decreases the severity of many ME/CFS 
symptoms101. Additionally, the tendency for mitochondrial function to decrease after exercise in 
some individuals (FIG 3.1, ME016, ME026, ME007) but not others (ME024, ME028) 
demonstrates that ME/CFS subtypes are very likely, with each individual having different 
pathways affected that lead to symptom presentation. Interestingly, control individual C012, 
which also had decreased mitochondrial function after exercise, exerted themselves greatly to 
reach the set work rate, as they had a high fitness level. This poses the question of whether 
ME/CFS individuals are, in fact, experiencing increased perceived levels of exertion due to a 
physiological difference, as extreme exertion also produced an “ME/CFS-like” drop in 
mitochondrial function.  
There were differences in the individual steps of mitochondrial energy production between 
ME/CFS-affected individuals and controls, though this was not extreme. Nevertheless, a 
surprising result was that ATP production was higher, on average, in ME/CFS affected 
individuals compared to controls (FIG 3.2, panel “C”). This supports the findings of Lawson, et 
al. 102, who found that ATP levels were higher in ME/CFS patients compared to controls. This 
finding contradicts that found in Missailidis, et al. 56.  
Another intriguing trend was that proton leak decreased over the course of the exercise paradigm 
in ME/CFS-affected individuals. The current opinion of the field is that decreased Complex V 
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(ATP-synthase) efficiency is associated with ME/CFS. Given this, one would expect increased 
proton leak, leading to decreased ATP production. Nonetheless, proton leak was found to be 
higher on average before exercise compared to controls. 
ME/CFS-affected individuals also had higher activities in each of the individual steps of 
mitochondrial energy production compared to controls (FIG 3.2). However, this may be due to 
the inclusion of one ME/CFS-affected individual, ME007, who had high levels of mitochondrial 
function overall, despite normalising the Seahorse data to adjust for variation in cell count 
between individuals (see FIG 3.3, for example).  
4.3. Oxidative Stress 
The levels of 8-OHdG did not increase in response to exercise in ME/CFS-affected individuals 
(see FIG 3.6 & FIG 3.8). This may be explained by the low yields of the gDNA used (see TABLE 
3.1). However, it is unlikely caused by the freezing process of the PBMCs, as the fresh and frozen 
control 8-OHdG levels were comparable (see FIG 3.7). 
Little research has been done on how 8-OHdG levels change within ME/CFS individuals during 
PEM, as done in this experiment. Substantial research has, however, been performed on the 
difference in oxidative stress levels between ME/CFS-affected individuals and controls. Many 
groups have shown increased levels of oxidative stress in those with ME/CFS 81, 85, though the 
weight of these findings is often overexaggerated 60, 103. One paper that looked directly at the 
levels of 8-OHdG in ME/CFS affected individuals performed their assay on urinary excretions, 
whereas this experiment was performed on the gDNA extracted from PBMCs 60. Maes and 
colleagues measured 8-OHdG residues that had been excised from the DNA by the cell’s DNA 
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repair enzymes, allowing them to travel through the blood and be excreted through the urine 104. 
Detection of 8-OHdG in our study, however, detected 8-OHdG within the DNA. The different 
types of 8-OHdG being measured may explain the differences in results observed  
Despite the minor difference in 8-OHdG concentrations between ME/CFS individuals and 
controls, the difference of 0.5 ng/μL may be substantial enough to act as a biomarker. Future 
research should aim to determine the scale of 8-OHdG variation between those with ME/CFS 
and controls with a larger cohort.  
4.4. DNA Methylome 
4.4.1. Context 
The study’s primary focus was the DNA methylome of ME/CFS patients, as recent 
publications have shown the interface of epigenetics and ME/CFS to be of great promise 66, 
68, 71, 89, 97, 105. It aimed to sequence the DNA methylomes of five ME/CFS subjects and two 
healthy controls, taking samples before and after exercise, to see how the DNA methylome 
changed in response to physical exertion and thus PEM. Unfortunately, due to sample 
failure, only one individual’s DNA methylome at baseline, after the first exercise (24 h), and 
after the second exercise (48 h), could be attained. Analysis was therefore shifted to a more 
“precision medicine” approach, looking at the changes within a patient rather than in 




4.4.2. Overall changes 
Significant differences in the DNA methylome from before exercise and then after exercise 
were found (FIG 3.14 & FIG 3.15). The large proportion in gene bodies and intergenic 
regions was expected, with Helliwell, et al. 97 and de Vega, et al. 89 observing this trend.  
Results of whole-genome analysis show disturbances in ion channels, blood vessels, HPA 
axis, neuronal development and proton leak, as depicted in table TABLE 3.4 & TABLE 3.5. 
These areas have all been previously associated with ME/CFS 56, 71, 72, 97, 106-108, so it is 
unsurprising to see their association with PEM.   
With regard to the promoter-based changes, the main pathways affected included 
metabolism, immune function, alterations to the nervous system and HPA-axis, as well as to 
the circadian rhythm.  
No published studies have shown how the ME/CFS DNA methylome changes during PEM. 
However, six papers at the time of writing examine the epigenetic changes in ME/CFS versus 
controls 66, 68, 71, 89, 97, 105.  
4.4.3. Metabolic Alterations 
Several studies have shown alterations to ME/CFS metabolism 53, 101, 107, 109, 110, with most 
linking these impairments to mitochondrial dysfunction53, 101, 109, 110. The hypomethylation 
of SLC25A14, encoding a brain mitochondrial protein responsible for proton leak and 
BEX2, which inhibits mitochondrial apoptosis, affirms the association of ME/CFS and the 
mitochondria. Limited study has been performed on how proton leak affects mitochondrial 
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apoptosis, though one study found that inducing mitochondrial proton leak prevented the 
initiation of mitochondrial apoptosis111.  
Intergenic methylation of another metabolic gene KLF14, increased after the first exercise 
(TABLE 3.4).  KLF14 regulates adipose tissue, potentially limiting adipose cell maturation112.  
Interestingly, a recent study proposed that KLF14 loss-of-function via promoter 
hypermethylation may trigger the onset of metabolic diseases112. As many papers have 
published metabolic disturbances in ME/CFS55, 109, 113, 114, pyrosequencing of this gene to 
confirm this finding in another cohort would be beneficial.  
4.4.4. Immune System Alterations 
Alterations to the immune systems of ME/CFS patients as a hallmark of the disease has long 
been accepted, and therefore it is not surprising that genes such as TRIM16L and ARC, 
immune-related genes, are linked to PEM (see TABLE 3.6). The multi-functional nature of 
genes such as ARC further confirms the wide range of impairments seen in ME/CFS 
pathophysiology. 
4.4.5. Nervous System Alterations 
One interesting finding was the hypomethylation of POU3F4, which is normally present in 
high concentrations in the basal ganglia. This disturbance may explain some of the 
symptoms observed during PEM. Activation of the basal ganglia, which interacts with the 
limbic system to regulate motor activity and motivation, has been found to be decreased 
among ME/CFS-affected individuals115. Interestingly, decreased activity of the basal ganglia 
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has also been linked to individuals with chronic immune stimulation, which is present in 
ME/CFS.  
Additionally, detection of hypermethylation of KCNJ12, which regulates circadian 
entrainment, supports the findings of Sweetman, et al. 114. Circadian rhythm impairment has 
been shown to lead to sleep disturbances, pain, fatigue, light and sound sensitivity116, as well 
as disruptions of the metabolic117 and immune systems118, all of which are observed in 
ME/CFS. 
One area of great promise is the involvement of the HPA-axis in ME/CFS. Several studies on 
the topic have been conducted 71, 72, 74, 79. In this study, methylation of SOX3, a gene that 
regulates HPA-axis formation, was found to decrease after exercise from both the baseline 
sample to after the first exercise, but also after the second exercise as well. Whilst this gene 
has only been reported to be involved in the formation of the HPA-axis, further validation 
in another cohort should be performed, as SOX3 was found to be part of a strong protein 
interaction network upon analysis with STRING91 (FIG 3.16, panels “B” and “D”).  
Because of this reason, study data should be made available in a shared pool to employ machine-
learning approaches, as suggested by de Vega and McGowan 74. This will allow the aggregation 
of data from multiple fields, such as epigenetics, cardiac physiology, proteomics and genome-
wide association analyses, producing a more coherent picture of the most common findings 




4.5. Limitations & Future Directions  
There are various study limitations, predominantly due to the limited number of participants, 
especially regarding the DNA methylome study. Given the unavoidable circumstances, however, 
the findings are still of value when interpreted through a “precision-medicine” lens, focussing on 
changes within the patient and using them as their own control.  
However, sedentary controls, as used in other ME/CFS studies38, 40, 119, 120 should have been used, 
as they more correctly match the level of activity ME/CFS individuals exhibit.  
Despite this, the inclusion of a non-sedentary control, who cycled for much longer to reach their 
peak work rate, and thus had a higher level of exertion, revealed an important trend. This was 
that, based on their Seahorse XF Cell Mito Stress Test profiles, ME/CFS individuals appeared to 
have exerted themselves much more than expected given their duration of cycling (FIG 3.1).  
Nonetheless, additional changes to the study design should include a non-exercise control. This 
would have allowed the distinction between exercise-induced changes and normal fluctuations 
within an ME/CFS-affected individual over time. To further strengthen the study design, each 
patient could have also acted as their own control, giving blood three times over 48-hours 
without PEM symptoms, then again during the exercise paradigm.  
A large drawback to the mitochondrial study is that frozen live cells were used when measuring 
participants’ OCR using the Seahorse XF Cell Mito Stress Test. When cells are frozen, the 
integrity of the inner mitochondrial membrane is jeopardised121. The unbroken membrane is 
required for electron transfer between the electron transport chain complexes, which ultimately 
fuels ATP synthesis. Therefore, it is unknown whether the inner mitochondrial membrane was 
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intact when we performed the stress test; thus, we cannot be sure our data accurately reflects the 
OCR of each participant. The accepted methodology is instead to use fresh cells extracted within 
one hour of performing the stress test.  However, a recently published paper by Osto, et al. 121 
details a protocol designed to measure the OCR of previously frozen cells without disrupting 
this membrane, involving snap freezing in liquid nitrogen immediately after extraction. Either of 
these two changes should be employed if a new Seahorse XF Cell Mito Stress Test is to be 
performed.  
 
Future research should reassess how mitochondrial function changes during PEM in ME/CFS 
individuals, employing the suggested methodology mentioned in paragraph above. 
4.6. Conclusions 
In summary, changes were observed in the oxygen consumption rate of ME/CFS subjects, as well 
as evidence of a difference between ME/CFS patients and healthy controls. The similarity in 
OCR profiles between ME/CFS-affected individuals and an over-exerted control should be 
further explored, as it potentially links the “increased perceived exertion” hypothesis with a 
physiological output. The statistically significant decrease of ATP production after exercise 
should also be explored, potentially explaining the fatigue ME/CFS sufferers experience. 
8-OHdG levels, as a measure of oxidative stress, did not appear to have drastic changes during 
the exercise paradigm, nor between ME/CFS individuals and controls. However, the spread of 
8-OHdG levels in ME/CFS and healthy individuals should be assessed, as we cannot conclude 
that this minor difference is not, in fact, significant enough to act as a biomarker for ME/CFS. 
Finally, significant differences in the DNA methylation of one individual’s genome was observed 
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throughout the exercise paradigm, especially in genes related to the HPA-axis and immune 
system, metabolism, and circadian rhythm. 
These findings buttress those reported by many other research groups. Whilst many researchers 
have investigated ME/CFS by comparing it to controls, the investigation of its key symptom, 
PEM, is underdeveloped. Therefore, this thesis contributes to filling a major gap in the field. 
Additionally, this study employs a “precision medicine” approach, using patients as their own 
controls. Because of the fatigue-induced limitations of those with ME/CFS in partaking in 
studies, genome-wide investigations employing thousands of participants are not possible. This 
project provides an alternative, which, with increased sharing of data and machine learning, may 
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